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One of the primary limitations of RNA interference as a technique for gene 
regulation is effective delivery and transfection of siRNA into the target cells.  
Dendrimers and polyethyleneimine (PEI) polymers are nanoparticles being developed 
as non-viral vectors for oligonucleotide and drug delivery. Through two separate 
collaborations with other research groups, we have gained access to novel carbosilane 
dendrimers (CBS) and polyethylene glycol (PEG)-engrafted PEI copolymers in order 
to research the potential these vectors have at inhibiting HIV replication by siRNA 
delivery. Initially, stability and structural dynamics studies were carried out to 
examine the characteristics these structures possess when complexed with siRNA. 
These experiments showed that CBS protected siRNA from RNase degradation and 
that its structural design resulted in a gradual liberation of the siRNA cargo.  
Cytotoxicity assays of dendriplexes with a variety of cell types revealed a maximum 
safe dendrimer concentration for in vitro assays. Similar experiments performed with 
polyplexes highlighted the improvement in biocompatibility achieved by PEG 
engraftment.  PEI-PEG polymers had minimal effects on cell viability. Next, through 
the use of flow cytometry and confocal and immunofluorescence microscopy, 
lymphocytes and astrocytes were seen to be successfully transfected with fluoro-
chrome-labeled siRNA either alone or complexed to the delivery vectors. Further-
more, transfection efficiency assays helped to decide the best ratios of vector amine to 
nucleotide phosphate for cell transfection and to determine the size and number of 
PEG-engraftments to achieve maximum uptake by the cells. Barriers made of cell 
monolayers were utilized to test the potential of dendriplexes to cross biological 
barriers with the objective of using this delivery method to reach cells of the central 
nervous system (CNS). The final set of experiments dealt with gene silencing by 
siRNAdelivered by these vectors. The GAPDH gene was silenced by dendriplexes 
nearly 50% after a short incubation, and polyplexes were seen to silence it by an 
average of 80% over the course of three weeks. The primary goal of the project was 
achieved when siRNA delivered by a PEI-PEG polymer resulted in the stable 
inhibition of HIV replication for 15 days to levels comparable to AZT, a top 
antiretroviral drug. Taken all together, these results point to the possibility of utilizing 
these non-viral vectors to deliver and transfect siRNA into lymphocytes or possibly 
cross the blood brain barrier and reach cells of the CNS, which would thus, in turn, 
improve the possibility of RNA interference as a potential alternative therapy for HIV 
infection. 
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Una de las primeras limitaciones del ARN pequeño de interferencia (siRNA) 
como técnica para la regulación de genes es su efectiva transfección y liberación del 
siRNA en el interior de las células diana. Los dendrímeros y los polímeros 
polietilenimina (PEI) son nanopartículas que se han desarollado como vectores no virales 
para la liberación de oligonucleótidos y fármacos. A través de dos colaboraciones con 
otros grupos de investigación, hemos tenido acceso a nuevos dedrímeros carbosilano 
(CBS) y copolímeros PEI unidos a una o más moléculas de polietilenglicol (PEG) con el 
fin de investigar el potencial que estos vectores tienen en la inhibición de la replicación 
del VIH mediante la liberación de siRNA.  Inicialmente, se han llevado a cabo estudios 
de estabilidad y dinámica estructural para examinar las características que estas 
estructuras poseen cuando se acomplejan con siRNA. Los experimentos han mostrado 
que los CBS protegen a los siRNA de la degradación por RNasas y que la liberación del 
siRNA es gradual. Ensayos de citotoxicidad de dendriplexes en una selección de tipos 
celulares han mostrado una concentración máxima de dendrímero segura para ensayos in 
vitro. Se han llevado a cabo experimentos similares con polyplexes destacando la mejora 
en la biocompatibilidad lograda tras la unión de los polímeros con PEG. Los polímeros 
PEI-PEG apenas han tenido efecto en la viabilidad celular. A continuación, mediante el 
uso de citometría de flujo y de microscopía confocal o de inmunofluorescencia, se ha 
observado que tanto linfocitos como astrocitos se transfectan con siRNA marcado con un 
fluorocromo tanto solo como unido a vectores de liberación. Además, ensayos de 
eficiencia de transfección han ayudado a determinar los mejores ratios de carga y el 
tamaño y número óptimos de moléculas PEG para conseguir una máxima internalización 
por las células. Con el fin de usar estos métodos de liberación para alcanzar las células 
del sistema nervioso central (SNC), se han utilizado dos modelos distintos de barreras 
biológicas para testar el potencial de los dendriplexes en cruzarlas. El ultimo grupo de 
experimentos ha consistido en el silenciamiento de genes mediante la liberación de 
siRNA por estos vectores. Se ha conseguido silenciar el gen GAPDH en casi un 50% tras 
un corto periodo de incubación con dendriplexes y en un 80% tras tres semanas de 
tratamiento con poliplexes. El objetivo principal de este proyecto se ha alcanzado cuando 
la liberación de siRNA por un polímero PEI-PEG ha resultado en una inhibición estable 
de la replicación del VIH durante quince días a niveles comparables a los del fármaco 
antirretroviral AZT. En conjunto, nuestros resultados apuntan a la posibilidad de utilizar 
estos vectores no virales para transfectar y liberar siRNA en linfocitos o atravesar la 
barrera hemato-encefálica y alcanzar las células del SNC, lo cual mejoraría el uso 
potencial del ARN de interferencia como terapia alternativa en la infección por el VIH. 
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1.1 The Human Immunodeficiency Virus (HIV) 
The global HIV/AIDS pandemic is the largest threat to worldwide health, 
safety and economy that will likely be faced in our generation. Since the first cases of 
AIDS were recognized in 1981 [1], more than 25 million people have succumbed to 
the disease. Another 33 million individuals are currently infected with HIV, according 
to 2008 estimates by the World Health Organization [2]. These numbers qualify 
HIV/AIDS as a pandemic [3]. The geographical area most affected by HIV/AIDS lies 
in Sub-Saharan Africa where 33 (67%) of the 49 least developed countries1 in the 
world [4] and two thirds of all HIV positive cases in the world are located. In this 
region, the adult prevalence2 of HIV infection has reached 5% [2], and the pandemic 
has had enormous effects on public health, life expectancy, population dynamics, 
numbers of orphaned children and local economy because of the loss in human 
capital. Figure 1 shows an example of the effect that AIDS has had on the average 
life expectancy in several of the worst affected countries. Sub-Saharan Africa is 
indeed the region that is worst affected by HIV/AIDS. However, the myriad of dan-
gers and problems caused by this infectious disease pandemic affects the entire world. 
Therefore, there is a great deal of need for research into preventive strategies, 
developing new therapies, improving current treatment, and searching for an effective 
vaccine. The effect this pandemic has on social, cultural and economic issues is 
greatly increasing every year. And yet, there still is no vaccine or cure for the disease 
and treatment consists of a rigorous life-long regimen of high-cost antiretroviral 
medications. 
                                                
1 The UN classifies countries as “least developed” based on three criteria: (1) annual gross domestic product 
(GDP) below $900 per capita; (2) quality of life, based on life expectancy at birth, per capita calorie intake, 
primary and secondary school enrollment rates, and adult literacy; and (3) economic vulnerability, based on 
instability of agricultural productions and exports, inadequate diversification, and economic smallness. Half or 
more of the population in the 49 least developed countries are estimated to live at or below the absolute poverty 
line of U.S. $1 per day. 
 
2 Proportion of adults aged 15-49 who are living with HIV/AIDS 
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Figure 1. Life expectancy in five Sub-Saharan African countries (Botswana, Kenya, South 
Africa, Uganda, and Zimbabwe) from 1958 to 2003. (Source: World Bank, World Development 
Indicators, 2004) 
The causative agent of AIDS is HIV, a lentivirus and member of the retrovirus 
family. Transmission of HIV between individuals can occur via unprotected sexual 
contact, through the exchange of blood or blood products such as through blood 
transfusions or by sharing needles for intravenous drug use, or from mother to child 
either during gestation, at birth or during breast-feeding. HIV primarily infects the 
human immune system cells CD4+ helper T lymphocytes, macrophages and dendritic 
cells. During the course of HIV infection, persistent viral replication, aberrant and 
persistent immune activation and, eventually, immunological deterioration are known 
to occur [5]. HIV infection consists of four stages referred to as incubation, acute 
infection, latency, and AIDS. Acute HIV infection involves high HIV viremia and a 
sudden drop in CD4+ T cells due to a very high viral replication rate and a 
dissemination of infected CD4+ T cells by activated CD8+ T cells. This stage persists 
an average of two weeks during which time the individual may exhibit flu-like 
symptoms [5, 6]. Afterwards, the infection enters a stage of clinical latency lasting an 
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average of 10 years for untreated patients, when the plasma viral load (VL) drops and 
CD4+ T cell counts rebound before gradually falling to levels where proper immune 
system function cannot be maintained. At this point, the patient is susceptible to a 
myriad of opportunistic infections, the contraction of which indicates a progression to 
AIDS, the final stage of HIV infection (Figure 2). The course of the disease 
progression can be accurately monitored by measuring VL and CD4+ T cell counts 
[7, 8]. In untreated patients, HIV infection followed by the development of AIDS is 
invariably fatal. 
 
Figure 2. Generalized graph showing HIV RNA copies (viral load) and CD4+ T cell counts over 
the average course of untreated human HIV infection. (Modified from Fauci et al. (1996))  
1.1.1 HIV genome 
Virions of the HIV virus, like all retroviruses, consist of an envelope structure 
composed of viral envelope glycoproteins (Env) and a lipid bilayer that encloses 
viral structural proteins (Gag), enzymatic proteins (Pol) and two copies of an RNA 
genome (see Figure 4). The genome consists of nine genes that encode 15 principal 
proteins (Figure 3).  
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Figure 3. The HIV genome consists of 9 genes that encode 15 proteins. (Source: Greene, et al. 
(2002)) 
• LTR – The genome is flanked on both ends by a non-coding repeated 
sequence termed the long terminal repeat (LTR), which is necessary for 
the viral genome to be inserted into a host cell’s DNA, and also functions 
as a transcriptional promoter. 
• Gag – The gene gag encodes for the three structural proteins matrix 
(MA), capsid (CA), and nucleocapsid (NC), which are formed from the 
cleavage of the Gag polyprotein by the HIV protease. 
• Pol – The pol gene encodes for a polyprotein containing all three en-
zymatic proteins. The transcript from this gene is produced when a frame 
shift occurs when the gag gene is being transcribed so that the gag stop 
codon is missed and the pol gene is transcribed as an appendage to the 
gag mRNA. This error in transcription occurs about 5% of the time [9]. 
The resulting polycistronic mRNA is translated into the polyprotein Gag-
Pol. This polyprotein is likewise processed by protease to generate the 
Gag and Pol polyproteins and, subsequently, the three structural proteins 
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(from Gag) and the three enzymes protease (PR), reverse-transcriptase 
(RT), and integrase (IN). Each of these enzymes possesses a unique role 
in the propagation of the virus as is described below in more detail. 
• Env – The env gene encodes the gp160 envelope polyprotein. This gene 
product is translated in the endoplasmic reticulum and transferred to the 
plasma membrane by way of the Golgi apparatus where it is cleaved by 
cellular proteases and glycosylated to form the membrane bound gp41 
glycoprotein and the gp120 glycoprotein located in the Golgi lumen. The 
two Env glycoproteins are non-covalently bound to each other and, once 
they arrive at the plasma membrane, are incorporated into budding virions 
where they become responsible for receptor binding and fusion of the 
nascent virions during infection of new cells. 
• Accessory genes – The accessory genes vif, vpr, tat, rev, vpu, and nef are 
six additional genes contained in HIV that distinguish it (and other 
primate lentiviruses) from more basic retroviruses which only possess the 
essential gag, pol, and env genes [9]. They encode proteins that play a 
secondary role in HIV replication. These are the products of either singly 
spliced or multiply spliced viral mRNA. The Env proteins come from 
singly spliced transcripts, while unspliced whole transcripts are the 
precursors for the Gag and Gag-Pol polyproteins. Tat and Rev are 
essential for HIV replication, whereas the remaining accessory proteins 
are not required for viral replication in vitro [10], but serve additional 
purposes in the viral replication cycle. 
 
1.1.2 HIV structure 
HIV virions are very efficient in their structure, possessing only the necessary 
components for the first phase of the viral life cycle, from cell infection to integration 
into the host DNA. The genome is optimized to contain the necessary genes in the 
smallest amount of RNA possible. It takes advantage of multiple splicing sites, all 
three reading frames, and extensive overlapping to accomplish this [9]. An individual 
virion has a diameter of 100 to 150 nm [11]. The structural organization of the virus 
must be extremely efficient in order to contain two copies of an RNA genome as well 
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as all the proteins needed to enable infection and maintain stability in an environment 
as hostile as the extracellular matrix (Figure 4). 
 
Figure 4. A model for the structure of a mature HIV virion. (Adapted from NIAID image.)  Inset: 
3D reconstruction of authentic HIV virions from cryo-electron tomography. (Source: Briggs, et al. 
(2006)) 
1.1.3 HIV replicative cycle 
HIV follows a thorough step-by-step procedure consisting of two phases in 
order to reproduce. Every step and all of the components involved, either viral or 
from the host cell, are important (and in most cases essential) for HIV to maintain 
productive replication. A likely mode for HIV infection begins with the virus being 
presented to CD4+ T cells by macrophages or dendritic cells. The precise methods of 
cellular transmission in vivo have not been entirely determined, and likely depend on 
the route of transmission between individuals. What is more fully understood is what 
happens when the virion comes into contact with a susceptible CD4+ T cell. Cell 
entry can be achieved either by fusion or endocytosis, but fusion is required for 
productive infection to occur [12]. What follows is an explanation of each of the steps 
necessary for HIV to succeed at infecting a cell in order to replicate, and Figure 5 
illustrates HIV’s replicative cycle. 
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Figure 5. The replication cycle of HIV. Small arrowheads show fusion to integration. Curved arrows 
show early transcription of Tat and Rev. Double-headed arrows show late transcription to viral 
budding. (Source: Scherer, et al. (2007)) 
• Fusion – HIV fuses with the cell membrane upon association of the viral 
gp120 Env glycoprotein with the CD4 receptor and another chemokine 
coreceptor, primarily CCR5 for macrophage-tropic HIV strains (R5 viruses) or 
CXCR4 for T cell-tropic strains (X4 viruses) (Figure 5, point 1). Interaction 
of the gp120 with the target cell membrane receptor causes a conformational 
change in the viral protein exposing another viral glycoprotein, gp41, which 
brings the virus membrane close enough to the cell membrane for fusion to 
occur and the virus contents to enter the cell (Figure 5, point 2). 
• Retrotranscription – After fusion and access to the interior of the cell is 
achieved, the virus undergoes uncoating of the particle’s structural 
components (Figure 5, point 3), thus allowing retrotranscription of the viral 
RNA genome to take place. Retrotranscription is the process in which the 
single stranded RNA viral genetic material is retrotranscribed by the viral 
enzyme RT into double stranded DNA (Figure 5, point 4). Retrotranscriptase 
also contains an RNase H activity, which degrades the RNA template after the 
DNA strand has been synthesized.  
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• Preintegration complex and nuclear import – The viral DNA and several 
viral enzymes and structural and accessory proteins are packaged into a tight 
unit called the preintegration complex (PIC) (Figure 5, point 5). Formation of 
the PIC requires a great deal of compaction of the viral DNA [13]. The PIC 
travels along microtubules to reach the cell nucleus where it passes through a 
nuclear pore (Figure 5, point 6). The ability to gain access to the inside of the 
nucleus allows HIV to infect non-dividing cells such as resting T cells and 
terminally differentiated macrophages including microglia, in the brain. This 
is quite a feat considering nuclear pores are roughly half the diameter of the 
PIC. The mechanism for nuclear import is not entirely understood. 
• Integration – Facilitated by the viral enzyme, IN, the virus genome undergoes 
genetic recombination with the cellular DNA and is inserted into a host 
chromosome (Figure 5, point 7). The end result of recombination determines 
the efficacy with which the virus replicates. Integration into a transcriptionally 
active region of the host DNA results in active viral replication, while it is 
likely that integration into heterochromatin where transcription is repressed 
results in latently infected cells. These latently infected cells contribute to the 
latent stage of HIV infection and the inability to completely eliminate the 
virus from the host even when the plasma VL remains at undetectable levels. 
• Transcription – In transcriptionally active regions where HIV DNA has 
integrated, the HIV provirus is transcribed by the cell’s transcription 
machinery to produce the RNA transcripts necessary for viral replication. 
Transcriptional efficiency depends highly on the viral proteins Tat and Rev. 
Tat is known to bind with elements of the cellular transcription machinery and 
enhance transcription of full length HIV transcripts. It does this by binding to 
the trans-activation response (TAR) RNA element, a sequence that forms the 
5´- end of all HIV transcripts. Without Tat, only short incomplete transcripts 
are produced efficiently. Early on in the replicative cycle, short multiply 
spliced transcripts are produced and result in the expression of the viral 
proteins Tat, Rev and Nef (Figure 5, points 8,9). With the accumulation of 
Tat, partially spliced and full-length HIV transcripts can be transcribed more 
efficiently to produce the remaining viral proteins, including structural, 
enzymatic and the other accessory proteins (Figure 5, point 10). Rev is 
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essential for full-length transcripts to exit the nucleus (Figure 5, point 11) 
[14]. Insufficient levels of Tat and Rev may also contribute to viral latency, as 
new infectious virions are not produced in high numbers without the presence 
of these two proteins. When the threshold concentration of Tat and Rev is 
achieved, the second phase of viral replication, also called “late transcription”, 
is initiated when the cell begins to manufacture new virions at a high level. 
• Assembly and Release – With the transcription and translation of full-length 
viral transcripts into the Gag and Gag-Pol polyproteins accomplished (Figure 
5, point 12), all the viral elements and two copies of the RNA genome 
assemble, under the direction of Gag, at the plasma membrane (Figure 5, 
point 13). Meanwhile, Env is translated from singly spliced transcripts in the 
ER and transferred via the cellular vesicular pathway to the plasma membrane. 
Via lateral movement, the Env glycoproteins migrate to the site of budding 
where all the elements to be incorporated into the nascent virion are 
assembled, and a new virion buds off from the cell surface (Figure 5, point 
14). 
• Virion maturation – The newly synthesized virion is still in an immature 
form, and the Gag and Gag-Pol polyproteins must be processed by protease 
for a mature viral particle to form (Figure 5, point 15). The cleavage of Gag 
into MA, CA, and NC initiates the formation of the conical shaped viral core 
around the RNA genome (see Figure 4) [11]. Protease also cleaves Pol into 
RT, IN, and PR. The resulting mature virion is now ready to infect a new CD4 
expressing cell. 
 
1.1.4 Cellular targets for HIV infection 
As has already been mentioned, the primary target and breeding ground for 
HIV are CD4+ helper T lymphocytes and the lymphoid tissues where these cells are 
most concentrated, such as the thymus, lymph nodes, spleen, and other lymphoid 
organs [15]. Circulating T cells, dendritic cells, and macrophages are also infected by 
HIV. In addition to infection of cells by free HIV virions, another (and possibly more 
prominent) method of viral dissemination is via cell-to-cell interactions [16, 17]. This 
method is possibly involved in one of the proposed mechanisms by which HIV 
invades the central nervous system. Referred to as the “Trojan horse” hypothesis, HIV 
Introduction 
 
 
 
11 
infected monocytes enter the brain and infect astrocytes and other nervous system 
cells either through cell-to-cell contact or via the release of infectious virus after 
migrating from the blood stream across the blood-brain barrier (BBB). The other 
possible methods are (1) the crossing of the BBB by free virions either by migration 
between or via transcytosis through the endothelial cells of the barrier and (2) the 
release of HIV into the brain from infected BBB endothelial cells [18]. Many 
pathological manifestations arise, in part, because of the infection of nervous system 
cells including HIV-related encephalopathy and AIDS dementia complex [19, 20]. 
The ability of HIV to infect multiple cell types contributes to viral latency and the 
enormous difficulties of eradication. HIV infection of cells such as monocytes and 
dendritic cells cause less cytotoxicity in these cells than with helper T cells [21], 
resulting in a longer period for productive viral replication and a higher possibility of 
the virus at establishing latency. The cells that harbor integrated virus without 
undergoing apoptosis or being eliminated by the immune system offer a principle 
reason why cell transfection must be achieved for any potential therapy to be 
successful. Moreover, the identification and targeting of latently infected cells with 
novel therapeutics could potentially improve current therapy. Likewise, cell-to-cell 
transmission of HIV highlights the fact that reducing the viral load in circulation to 
below detectable levels is not sufficient to enact a cure, and that more specific 
antiretroviral activity at the cellular level is a necessity to address HIV infection. 
 
1.1.5 HIV infection and the central nervous system (CNS) 
 HIV infection is often accompanied by neurological disorders and 
neuropathological abnormalities. It has been estimated that 20–30% of HIV-infected 
individuals eventually develop HIV associated dementia (HAD), and although the 
introduction of highly active antiretroviral therapy (HAART) has reduced its 
incidence, mild forms still persist [22]. In fact, in the HAART era, infected patients 
are living longer and the prevalence of HIV-associated neurological disturbances is 
actually rising [22-24]. In addition, HAD represents the leading cause of dementia in 
people under the age of 60. At present, an effective pharmacotherapy for HAD is not 
available. Previous approaches to cope with HAD reflect the challenging complexity 
inherent in the treatment of AIDS patients [25, 26]. Complicating the issue, the BBB 
separates the blood from the cerebral parenchyma and prevents the penetration of 
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drugs into the CNS. This physical barrier is characterized by tight intracellular 
junctions and the absence of fenestrations limiting permeability for therapeutic 
molecules such us the majority of the antiretrovirals. Therefore, in addition to 
antiretroviral treatments an additional option for therapy needs to be developed. 
 
1.1.6 Solutions for HIV infection 
Current treatment for HIV infection involves the use of multiple therapies in 
order to control the replication of the virus. The development of HAART has allowed 
HIV positive patients to survive much longer and live healthier, happier lives by 
means of diminishing VL and allowing the recovery of the immune system [27]. 
However, the complexity of this treatment causes many problems with administering 
it effectively. Most notably, its high cost and the need for the treatment to be 
thoroughly monitored by a health professional make its availability in underdeveloped 
countries very limited, precisely where the pandemic is most serious and treatment is 
most needed [2]. 
Despite significant advances in HIV infection treatment options, the virus still is 
a difficult target to contend with. At the molecular level, the low fidelity with which 
the virus replicates its genome, based on the retrotranscriptase’s lack of proofreading, 
along with a high replication rate, cause a very high rate of mutation [28]. The net 
result, in addition to the existence of a wide spectrum of viral isolates, is that the virus 
can very easily generate resistances to drugs or escape mutants when a drug regimen 
is improperly interrupted [29]. This causes the need for changes or increases in the 
drug regimen resulting in higher secondary effects, another main concern with current 
HIV treatment [2]. HAART, or treatment consisting of a combination of several 
classes of antiretroviral drugs, is generally administered to try and prevent the 
emergence of drug resistant viral strains. However, in low- and middle-income 
countries, where not all antiretroviral drugs are available, the options for drug 
combinations are limited.  
One of the main reasons that there is no cure for HIV infection despite over 
twenty-five years of research is the inability to address viral latency in HIV infection. 
HIV does not simply infect immune system cells, use the cell machinery for its own 
replication, and then kill the cell. It is also capable of infecting certain cells and 
remaining inactive inside them for large periods of time before resurfacing later to 
Introduction 
 
 
 
13 
cause as much damage to the immune system as the initial infection [12, 30]. Viral 
latency prevents the complete eradication of the virus, because despite the efficacy of 
therapy at reducing HIV replication and achieving an undetectable plasma viral load, 
there appears to remain pools of latently infected cells, which reinitiate viral 
production when activated. Therefore, treatment can never be entirely discontinued. 
In the absence of a cure or vaccine for HIV infection, antiretroviral drugs have 
become the best method of addressing the HIV/AIDS epidemic. The first 
antiretroviral drugs were approved for use in the mid 1990s. HIV antiretrovirals fall 
into five categories: nucleoside or nucleotide reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, 
and entry inhibitors [31]. These drugs manage to reduce viral replication by inhibiting 
the viral processes necessary for replication through the use of molecules that 
function by binding the viral or host proteins involved and inactivating them or by 
mimicking the substrate of the enzymatic reactions. In just over ten years since the 
use of these drugs was initiated, antiretroviral therapy has had an immense impact on 
the outlook of this disease. Figure 6 shows how the estimated number of deaths 
globally has been affected in part by increased access to antiretroviral medication in 
developing countries [2]. 
 
Figure 6. Estimated number of adult and child deaths due to AIDS globally, 1990-2007. 
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Despite these advances, the HIV/AIDS pandemic will not be eradicated without 
substantial new developments and innovation. HAART treatment has made an 
immense impact on fighting the disease, but it still possesses major drawbacks such as 
the necessity of maintaining greater than 95% adherence for it to be effective and the 
fact that it is a life-long therapy. Additional problems with drug cost and availability, 
treatment side effects, the emergence of drug resistance, the wide array of viral 
isolates, high mutability of the virus, and coinfections with other diseases such as 
tuberculosis or hepatitis, among many other issues, demand that research into 
addressing HIV infection be continued and further expanded with the objective of 
making new discoveries and improving current therapies. 
  
1.2 Gene Therapy and RNA interference 
The concept of altering the function, expression or translation of abnormal or 
disease causing genes has led to the development of such techniques as gene therapy 
and RNA interference (RNAi). Gene therapy deals with the introduction of genetic 
material (RNA or DNA) into target cells that encodes a protein that is missing or 
defective in order to achieve therapeutic objectives. Since it was first developed in the 
seventies, eighties and nineties, gene therapy has gone through major advances and 
tragic setbacks. However, possibly its most outstanding impact on biology and 
medicine was the introduction of the concept that disorders can be addressed by 
attacking them at their foundation, at the level of genes. The success of this idea has 
led to further developments in modifying specific gene functions through 
transcriptional, post-transcriptional or translational regulation such as antisense 
oligonucleotides, ribozymes and RNAi. 
 RNAi is an innate defense response to the introduction of double-stranded 
RNA into cells resulting in a sequence-specific downregulation of genes with the 
same or similar sequences to the introduced RNA. Andrew Fire, Craig Mello and 
colleagues first discovered RNAi in Caenorhabditis elegans in 1998 [32] for which 
the pair received the Nobel Prize in 2006. In the eleven years since that discovery, 
there has been a steady increase in research dedicated to RNAi and the utilization of 
RNAi to silence genes as can be seen in Figure 7. Both the total number of articles 
dealing with gene therapy or RNAi and the percentage of this topic dedicated to 
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RNAi have steadily increased. In 2008, 70% of the nearly 8000 articles on this topic 
indexed in Pubmed mentioned RNAi in the title or abstract. 
 
Figure 7. Gene therapy articles indexed in Pubmed. A steady increase in both total number of gene 
therapy (GT) articles and articles dedicated to RNAi. 
 
1.2.1 Mechanism of RNA interference 
The mechanism behind RNAi consists of several parts. First, upon the 
introduction of a double-stranded RNA (dsRNA) into the cell, a cellular protein 
termed Dicer recognizes the foreign element and cleaves it into short double-stranded 
RNA segments of between nineteen and twenty-three base pairs. These short 
segments have been termed small interfering RNA (siRNA). Second, the siRNA are 
incorporated into a large protein complex called the RNA inducing silencing 
complex, or RISC, which separates the strands and uses the antisense strand as a 
template to recognize complementary mRNA via Watson-Crick base pairing and 
degrade them. Thus, gene transcripts are downregulated post-transcriptionally but 
prior to translation. In this way, the RNAi mechanism effectively silences the 
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production of genes from exogenous RNA invaders in a sequence-specific manner 
(Figure 8) [33]. 
 
Figure 8. Mechanism for gene silencing by RNAi. (Source: www.5ibio.com/html/ 
RNA/RNAi/20061111/1427.html) 
 The RNAi mechanism pathway can be initiated with either long double-
stranded RNA or by skipping the cleaving step performed by Dicer and directly 
introducing siRNA into the cell cytoplasm. In this way, the RNAi mechanism can be 
hijacked, and a gene can be targeted for downregulation by designing and transfecting 
the cell with siRNA possessing a complementary sequence to the target mRNA. One 
of the benefits of skipping the step involving Dicer is that the introduction of large 
dsRNA induces an innate immune interferon response in mammals which is avoided 
with treatments of the smaller siRNA [34]. In-depth studies have determined the size 
and structure of the siRNA products of Dicer digestion in great detail, and their design 
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and synthesis have been optimized in order to achieve the highest efficiency in gene 
silencing. The general structure of siRNA consists of two complementary RNA 
strands 21 nucleotides long. The two RNA strands form complementary base-pair 
interactions in such a way that on each strand only the first 19 nucleotides (from 5´ to 
3´) bind with the first 19 nucleotides of the other strand leaving an overhang of two 
nucleotides on each 3´ end (Figure 9). The two nucleotide overhangs on each end 
come about as a result of the way Dicer cleaves the longer dsRNA, and they function 
to identify the siRNA for incorporation into the RISC complex to act as the template 
for target mRNA recognition [35]. 
 
Figure 9. In this example of a typical siRNA, base-pairs form between the “core” 19 nucleotides of the 
two strands leaving an overhang of two nucleotides on each end of the siRNA. In this case the 
overhangs consist of two deoxynucleotides (thymine) instead of ribonucleotides to improve stability 
and resistance to nucleases. (Source: www.invitrogen.com) 
1.2.2 Other utilizations of the RNAi mechanism 
Several other regulators of gene expression such as micro RNAs (miRNA) and 
small hairpin RNAs (shRNA) also utilize the RNAi mechanism to downregulate 
specific genes. It has been discovered that miRNAs are endogenous short auto-
complementary RNA strands that buckle in on themselves to form stem-loop 
structures, are processed by Dicer in the same way as dsRNA, and function as 
naturally occurring gene regulators by targeting specific mRNA transcripts and 
inhibiting their translation [36]. It seems that miRNA are naturally encoded and 
expressed in the genome of most animals and plants, and they function as one of the 
many tools cells have for regulating gene expression. Similarities and differences 
between miRNA and siRNA are constantly being found leading to a further 
understanding of the RNAi mechanism and ways to take advantage of it for 
therapeutic objectives. shRNA is a powerful laboratory tool to specifically target 
genes for downregulation that differs from siRNA in that instead of transfecting 
siRNA, plasmids expressing small hairpin transcripts are transfected into the target 
cells [37]. The shRNA transcripts form miRNA-like stem-loop structures and are 
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incorporated into the RNAi pathway in the same way. Transfection of shRNA 
expressing plasmids results in longer-lasting gene silencing activity due to the 
constant recycling of active siRNA via transcription of the transfected plasmid. 
However, achieving transfection of the larger plasmid into the target cells is more 
challenging than the smaller siRNA. 
 
1.2.3 Applications of RNA interference 
In only just over a decade of research on RNAi, a great deal of achievements 
has already been made in this area. Thus far, the primary use of RNAi has been as a 
tool for the identification of genes. The sequencing of the human genome has allowed 
researchers to identify previously unknown genes. However, in many cases, only the 
gene sequence is known without any knowledge of the function of the coded protein. 
By very effectively targeting and silencing a gene of any sequence, RNAi is being 
utilized as a rapid and highly specific method for testing loss-of-function phenotypes 
[38, 39]. The ability to knockdown a specific gene in such a simple way is a huge 
advancement from previous laboratory methods of gene regulation such as other 
forms of gene therapy or transgenic models. Molecular biologists are beginning to 
utilize this technique for a myriad of other objectives. In addition to testing individual 
gene function, whole siRNA libraries have been developed including genome-wide 
screens that can test the involvement of any of the approximately twenty-one 
thousand human genes in everything from hereditary diseases and oncogenesis to 
viral infection. 
However, RNAi is not only a powerful laboratory tool. Research in siRNA 
and shRNA as therapeutics is constantly expanding. A huge array of medical 
afflictions such as genetic disorders, cancers, neurodegenerative disorders, and 
infectious diseases such as HIV and hepatitis are being addressed by applying RNAi 
research to human cells in vitro. Considering the great achievements reached and the 
tremendous potential of RNAi, it is not surprising that in vivo studies were initiated 
very soon after its initial discovery. Much like the difficulties encountered in 
transfecting target cells with siRNA in vitro, systemic application of siRNA in vivo 
must overcome many hurdles before this technique can be utilized in designing new 
therapies. The primary obstacles for siRNA are degradation by nucleases in the blood 
stream and achieving localized targeting. The first in vivo studies with RNAi either 
Introduction 
 
 
 
19 
involved localized administration or targeting tissues in the liver or spleen where 
systemically administered siRNA is more readily taken up. To address stability of 
siRNA in the blood stream, methods for achieving cell transfection have also needed 
to serve double as protective agents as well as drug delivery vehicles (covered further 
in section 1.3 Drug Delivery). 
Gene therapy took a tremendous hit in 2003 when one of the initial clinical 
trials involving gene transfer resulted in leukemia in five out of twenty subjects 
including one death [40-42], despite successfully abating a genetic disorder called X-
linked severe combined immunodeficiency. It turned out that the retroviral delivery 
agent that was used to achieve transfection and integration of the induced gene into 
the target hematopoietic stem cells caused the activation of an oncogene promoter 
resulting in the leukemia. Following this episode, many clinical trials with gene 
therapy were put on hold and a greater effort was put on optimizing the method of 
delivery and transfection with an emphasis on research into non-viral vectors. Despite 
the difficulties encountered with extending gene therapy to clinical trials, several so-
far-successful clinical trials with RNAi are currently being carried out (Table 1).  
Table 1. RNAi in clinical trials. 
 
Based on Refs. [34, 43, 44] 
 
1.2.4 Targeting HIV with RNA interference 
 Very early on in the development of RNAi as a gene silencing technique, 
studies were started with the idea of utilizing this technique to treat or prevent HIV 
infection. Initial experiments showed that siRNA and shRNA could successfully 
inhibit HIV replication in vitro in either cell lines or primary lymphocytes by 
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targeting viral RNA sequences [45-48]. Figure 10 shows the HIV genes that have 
been targeted by RNAi, which have achieved varying levels of success at reducing 
viral replication. The fact that the HIV genome is transcribed in its entirety in order to 
produce the viral structural and enzymatic proteins [49] means that siRNA targeted to 
any region of the HIV genome will result in a downregulation of all viral products not 
only the gene that is specifically targeted [50]. Further studies revealed that when 
undergoing longer periods of treatment with siRNA or shRNA, HIV was able to 
mutate in order to avoid pressure from RNAi and escape treatment even when RNAi 
was targeted a highly conserved region of the HIV genome [45]. Even more 
interestingly, the virus was found to be able to mutate in a way that the secondary 
structure of its RNA transcripts changed so that the sequence targeted by RNAi was 
occluded from access by the RISC complex [51]. As had been the case with so many 
other anti-HIV therapies, it seemed that this new technique would not be immune to 
viral drug resistance. In any case, much has been achieved by attempting to utilize 
RNAi for the inhibition of HIV including targeting cellular factors necessary for viral 
replication such as CCR5 [46, 52, 53], in vivo studies with antibody-delivered anti-
HIV siRNA to human immune system cells transplanted into immunodeficient mice 
[54], and several clinical trials in HIV-infected patients [43]. These accomplishments 
have been made despite (and by always keeping in mind) the multiple difficulties that 
must be solved like delivery, transfection, siRNA degradation, and viral escape. 
 
Figure 10. HIV genes successfully targeted by RNAi: 
5´LTR (Refs. [45, 55, 56]); gag [57-59]; pol [58, 59]; vif [60-62]; tat [55, 61, 63, 64]; rev [63-65]; env 
[65, 66]; nef [62, 67]. (Image from Greene, et al. (2002)) 
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1.2.5 Problems that face RNA interference 
 Despite the enormous possibilities of RNAi, there still exist many problems 
that need to be addressed. As previously mentioned, obstacles in delivery, target cell 
transfection, stability/degradation, transient activity, secondary effects, toxicity 
caused by delivery vector, and resistance all hinder the path of carrying out in vivo 
experiments with RNAi and further developing RNAi as a new therapy for clinical 
use. As will be described in the next section, a great deal of these issues can be 
addressed by using the correct delivery vector. Because of this, a great deal of 
research is being put into finding a suitable partner and chauffeur for these valuable 
small nucleic acid molecules. The ideal delivery agent should protect the siRNA from 
degradation, transport it to the target cells or tissues, facilitate its transfection into the 
cytoplasm of the cells and all the while remain fairly innocuous and cause little or no 
adverse effects. 
 
1.3 Drug Delivery 
As has already been mentioned, the main limiting problems with developing 
gene therapy and RNAi into pharmaceuticals are their ineffectiveness in vivo and the 
difficulties in converting them into clinical therapies. Although some success has 
been achieved by localized delivery to such areas as the eye, skin, or local tumors [68-
72], systemic RNAi therapy still faces many issues [34]. These problems arise from 
the difficulty of directing the plasmids or oligonucleotides to target cells or tissues 
and then being able to successfully transfect them into the cell [73-75] where they can 
exert an effect. In vivo, free oligonucleotides are rapidly filtered from the blood by the 
kidneys or are processed by the reticulo-endothelial system and delivered to the liver 
and spleen [43]. This causes problems if the target cells are located in other regions of 
the organism. Furthermore, oligonucleotides, siRNA and plasmids are very unstable 
once in circulation because of the presence of nucleases and serum proteins in the 
bloodstream which sequester and degrade these potential therapeutic agents. The area 
of study dedicated to addressing these problems is termed “drug delivery”. Despite 
the existence of several methods that allow successful transfection of cells with 
oligonucleotides in vitro, transferring these methods to in vivo studies is often 
unfeasible. 
 
Weber, N. 
 
 
 
22 
1.3.1 Physiological obstacles to systemic RNAi therapy. 
There exist numerous problems with applying systemic RNAi therapy in vivo 
(Figure 11). Aside from the stability, degradation and filtration issues in the 
bloodstream (Figure 11a), there are several other barriers that must be overcome if 
the delivery system can achieve stability in circulation. Crossing the vascular 
endothelial barrier presents a problem for most delivery systems (Figure 11b). This is 
especially true in the CNS where difficulties in crossing the BBB with small molecule 
pharmaceuticals are widely recognized. It is believed that particles with diameters 
greater than 5 nm do not readily cross the vascular endothelial barrier. Some organs 
including the liver, spleen, lungs, and kidneys can be reached with larger molecules 
due to accumulation in the reticulo-endothelial system, which is a method of 
eliminating foreign particles from circulation. Likewise, some tumors can be accessed 
with larger molecules because of increased vasculature permeability in tumors 
referred to as the enhanced permeability and retention effect [34]. However, for 
diseases involving leukocytes or other parts of the immune system, obtaining stable 
circulation in the bloodstream may be sufficient to reach all the cells affected by the 
disease. HIV infection and other immunological disorders fall under this category. 
Although, the extent to which the virus may infect other non-immune system cells 
such as neuronal cells [76] and establish regions of latently infected cells that do not 
circulate throughout the blood stream is still under investigation. Once across the 
endothelial barrier, the extracellular matrix poses a myriad of obstacles like 
polysaccharides and fibrous proteins that hinder the progression of the treatment on 
their path to the target cells (Figure 11c). 
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Figure 11. Physiological Barriers to the systemic delivery of siRNA vectors. A systemic delivery 
system confronts numerous obstacles in reaching its objective: a) filtration, degradation and 
phagocytosis in the blood stream; b) crossing the endothelial barrier; c) transversing the extracellular 
matrix to the target cell; d) cell transfection; e) endosomal escape: f) delivery of siRNA to cell 
cytoplasm. (Source: Whitehead, et al. (2009)) 
Whether the target cells must be reached by crossing the endothelial 
membrane and penetrating the thick forest of the extracellular matrix or are reached 
from within the blood stream, the barrier of crossing the cell membrane and gaining 
access to the interior of the cell is the next obstacle that must be overcome (Figure 
11d). Indeed, cell transfection/uptake is one of the principle topics in which research 
in drug delivery is dedicated [77]. The methods by which particles are taken up are 
receptor mediated endocytosis and membrane fusion [78]. Viral vectors utilize the 
viruses’ evolutionarily developed methods for evading obstacles and gaining entrance 
to the cell interior. Many of these vectors utilize cell membrane receptors to facilitate 
fusion with the membrane, which allows for the deposit of their genetic payload to the 
interior of the cell. Non-viral vectors face greater challenges in achieving entry into 
the cell. Non-targeted vectors are believed to interact with the cell membrane via 
electrostatic interactions that facilitate endocytosis. Targeted vectors utilize ligands 
that are recognized by cell membrane receptors and their association initiates 
endocytosis [79]. Endocytosis of delivery vehicles results in their localization into 
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endosomal vesicles from which the delivery system must achieve escape (Figure 
11e). If all these obstacles can be overcome, the final step to be completed is the 
release of the intact and functional DNA or siRNA so that it can exert its effect 
(Figure 11f). In the case of plasmid DNA delivery for gene therapy, the additional 
problem of achieving access to the cell nucleus must be addressed. 
 
1.3.2 Methods for transfection in vitro. 
As mentioned in the previous sections, in order to achieve any silencing effect 
with RNAi, the siRNA or shRNA expressing plasmids must overcome the obstacle 
course of hurdles and reach the interior of the cell. It has generally been accepted that 
the cellular uptake of free oligonucleotides does not readily occur for most cell types 
in vitro. Our experiences have indicated otherwise for lymphocytic and astrocytic cell 
lines and primary lymphocytes [80]. Notwithstanding, the majority of research that 
utilizes RNAi depends on a delivery vector of some kind. Drug delivery vectors can 
be divided into two different categories. Viral vectors are chiefly used to transport and 
deliver genes, while non-viral vectors are the method of choice for smaller 
oligonucleotides such as siRNA. 
 
1.3.3 Viral Vectors 
Viruses possess a highly evolved method of hijacking cells and depositing 
their genetic material into the cell interior in order to utilize the cellular machinery for 
reproduction. This capability has been taken advantage of by scientists attempting to 
insert therapeutic genes in the place of the viral genetic material [81]. By removing 
the viral genome or removing essential viral genes from the viral particles, the altered 
virus loses its virulence and functions only as an innocuous transporter of the drug. In 
this way, researchers can achieve very specific delivery to the cells of interest with 
very high transfection efficiency. More highly developed retroviral vectors utilize not 
only the structural components of the virus but also the enzymes used by the virus to 
transcribe its genome from RNA into DNA, direct it into the nucleus, and insert it into 
the DNA of the host cell (Figure 12). These vectors are highly useful for integrating 
genes into cells so that they are repeatedly transcribed and thus can achieve an 
intransient effect. Despite the advances in molecular biology that allow the creation of 
these theoretically innocuous vectors, there still are many problems surrounding their 
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use in patients. Many viral vectors are immunogenic and have issues with stability. 
Many can only infect dividing cells. Causing even more worry, retroviral vectors can 
insert the therapeutic genes into regions of the genome that can cause undesired gene 
activation. This was the case in the clinical trail that used gene therapy to treat SCID-
X1 children in which five of the twenty subjects developed leukemia [40-42]. In the 
end, these vectors have been derived from highly virulent pathogens and they still 
possess many of their disease causing attributes, and there exists a great amount of 
public uncertainty to the use of this technology since there always exists the risk of 
contamination with replication competent viruses. 
 
Figure 12. Retroviral vectors exploit the life cycle components of their naturally occurring 
counterparts to introduce a transgene into target cells (in this case Factor IX). (Source: Verma et 
al. (1997)) 
1.3.4 Non-viral Vectors 
In many cases, viral vectors are not a feasible option, and fortunately, there 
exist many kinds of non-viral vectors that can function just as well as viral vectors. 
Non-viral vectors can be based on lipids, peptides, polymers, nanoparticles or a 
combination of more than one of these (Figure 13). Lipid-based vectors are referred 
to as liposomes and are comprised of the same phospholipid molecules as cell 
membranes. They are taken up by cells via endocytosis and release their payload into 
the cell interior when the lipoplex phospholipids are rearranged from interactions with 
the phospholipids of the cell membrane in the endosomes [82]. The disadvantages of 
this type of vector are problems with stability, particle uniformity, incapability of 
Weber, N. 
 
 
 
26 
targeted delivery, and rapid clearance from circulation due to uptake. Peptide-based 
vectors link small peptides with oligonucleotides either via covalent bonds or 
electrostatic interactions between basic amino acid residues and the negatively 
charged oligonucleotide backbone. The peptides can be designed to specifically target 
certain cell types or to facilitate cell uptake. Cell-penetrating peptides are one 
example of this type of delivery vehicle. They are able to translocate the cell 
membrane and escort their cargo into the cell [83]. Translocation of the cell occurs by 
direct membrane penetration, endocytosis, or via the formation of a transitory 
structure.  
 
Figure 13. Examples of non-viral delivery vectors for siRNA. (Source: Kurreck (2009)) 
Polymer-based delivery systems utilize cationic polymers to bind DNA or 
other oligonucleotides. In addition to forming complexes with the DNA, many 
polymers are capable of condensing it down to a size that makes cell transfection 
possible (~100 nm) [84] (Figure 14). The DNA is condensed in a method similar to 
the way that histones and other nuclear proteins cause DNA to form supercoiled 
chromatin  [85] (at a compaction ratio of as much as 1000-fold in interphase). The 
benefits of using polymers are a great deal of flexibility in structural design, the 
possibility of attaching functional groups to the polymers, DNA condensing 
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capability, and the relative ease of polymer synthesis and handling compared to viral 
vectors which require the use of recombinant technology and involve the dangers 
inherent with working with attenuated viruses. Polymers also generally do not 
produce the same immune response as viral vectors, so they are better adapted for in 
vivo experiments. 
 
Figure 14. The polycation polylysine is capable of condensing DNA to a size that is more suitable 
for cellular uptake. (Source: Gene Delivery Group, University of Oxford Dept. of Clin. 
Pharmacology)  
The possibility of utilizing functional groups attached to the polymers can 
accomplish many different objectives. For example, targeting moieties or targeting 
peptides can function to direct the polymer vector to very specific cell receptors and 
therefore specific cells or tissues. As was commented before, receptor-mediated 
endocytosis results in the compartmentalization of the polyplexes into endosomes and 
eventually lysosomes where degradation of the polyplex will occur. Therefore, 
endosomal escape is a necessity for the DNA or siRNA to reach the cytoplasm. This 
can be accomplished via the use of endosomalytic features such as the attachment of 
fusogenic peptides. Some polycations such as polyethyleneimine (PEI) possess 
tertiary and secondary amine nitrogens that allow the polymer to become further 
protonated when in a lower pH environment such as that which exists inside 
endosomes. This additional protonation of the polycations, a characteristic that has 
been designated the “proton sponge” effect, is thought to cause swelling and eventual 
rupture of the endosomal membrane [86]. Nuclear localization signal peptides can 
potentially give the polymers access to the nucleus so that their cargo plasmid DNA 
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can be expressed by the cellular transcription machinery [87]. Also, hydrophilic 
shielding moieties such as poly(ethylene glycol) (PEG) can be attached to polymers to 
increase the time in circulation by increasing their biocompatibility and resistance to 
uptake by the reticulo-endothelial system and clearance from the blood stream [88]. 
These shielding attachments can also protect DNA or siRNA from degradation by 
serum nucleases as they reduce the interactions of the polyplex with blood 
components. Shielding moieties are grafted to polymers in several different ways, and 
research into the effect that number, size and length of PEG shielding moieties have 
on the overall biocompatibility of the polymers has revealed much about these groups 
[89]. This work will expand on that research as results with polymers possessing PEG 
moieties of different sizes and numbers will be reported here. 
 
1.3.5 Nanoparticles 
The constantly evolving field of research referred to as nanotechnology offers 
other methods for drug delivery. Nanoparticles (referring to particles with a diameter 
from 1 to 100 nm [90]) are being developed to function as drug delivery vehicles 
including transporters of DNA and oligonucleotides. Nanoparticles used for drug 
delivery share many of the same characteristics as polymers, but have a more highly 
specialized design and synthesis. Dendrimers, for example, are nanoparticles derived 
from polymer synthesis technology, but possess specific attributes such as 
monodispersity and symmetry (Figure 15). Like polymers, most nanoparticles used in 
drug delivery contain cationic groups that can bind oligonucleotides via electrostatic 
interactions. Due to their small size, nanoparticles can facilitate the uptake of DNA or 
oligonucleotides by cells by 1) condensing the nucleic acids considerably in size, and 
2) possessing the size necessary to be taken up by endocytosis. Some nanoparticles 
such as gold- or silica-based nanoparticles have obtained results in DNA transfection, 
but their entry depends on the use of other cell transfection methods like polymer or 
liposomal transfectants or through the use of a particle accelerator gun. Carbon 
nanotubes have shown positive results in delivering DNA to cell lines in vitro [91, 92] 
and siRNA into myeloid, dendritic and cancer cells in vivo [93, 94]. However, the 
most highly utilized type of nanoparticle for gene therapy applications is dendrimers.  
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Figure 15. Polymers to dendritic structures. Molecular synthesis technology can be applied to 
polymer science to improve structure and function of different drug delivery vehicles. (Source: Boas, et 
al. (2006)) 
1.3.6 Dendrimers 
Dendrimers are defined as nanoscopic, monodisperse, polybranched, synthetic 
polymers [95]. The term “dendrimer” comes from the Greek “dendros” for tree 
because of the tree-like or branching nature of the dendrimer structure. Due to a 
diameter size of from 1.5 to 15 nm [96], dendrimers are considered to be nanoscopic. 
Dendrimers are synthesized under highly controlled conditions so that the product is 
as close to completely monodisperse as possible. This characteristic comes from a 
system of synthesis in which many steps are followed to gradually create a uniform 
structure and all of the dendrimer molecules have the exact same structure. The 
reason for creating nanoparticles with such a specific structure is for the functionality 
that arises because of that structure. As in the case with proteins, the macromolecules 
that dendrimers were largely designed to imitate, structure determines function. The 
highly systematic synthesis allows for a great deal of control in size, shape and 
terminal group functionality [97, 98]. Dendrimers are synthesized by two different 
methods [99]. One method of synthesis called “divergent synthesis” generates the 
molecule from the core outwards, while the other, “convergent synthesis”, initially 
starts with the external functional groups and generates the dendrimer by joining the 
external branches together and working from the outside in.  
The dendrimer structure can be divided into three different parts: 
1. a central core from which the arms extend outward that contains a 
microenvironment protected by the external structural components, 
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2. multiple branching arms that radiate out from the central core whose 
structure, length and number can all be altered depending on the 
desired size and functionality, and 
3. external functional groups located at the periphery of the branches and, 
therefore, on the molecular surface. These groups generally provide the 
primary functionality of the dendrimer. 
Similarly, the dendrimer structure can be viewed as having layers, or 
“generations”. The number of generations that a particular dendrimer has depends on 
the number of branching or focal points that exist in the branching arms as they 
extend outward from the core (Figure 16) [100]. Since at each focal point, the number 
of arms extending outwards increases by at least a multiple of two, the higher the 
generation, the greater the number of functional groups at the extremities. For a 
typical dendrimer that doubles the number of exterior branches at each focal point, a 
fourth generation dendrimer would possess thirty-two functional groups at the 
periphery. 
 
Figure 16. In this fourth generation polyamidoamine (PAMAM) dendrimer, the core and first 
generation are shown in blue, and each successive generation is shown in a different color. 
(Source: Castriciano, et al. (2008)) 
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 Monodispersity refers to the homogeneity in which the dendrimers are 
synthesized (i.e., all dendrimer molecules are made with the same structure, 
generation, and amount of branching). The branching structure of dendrimers allows 
them to possess multiple functional groups on the branch extremities all radiating out 
from a central core [101]. A primary advantage of dendrimers is the flexibility in 
which they can be generated. This allows for a wide variety of functional groups to be 
located along the branches as well as at the far extremities. The structure of the 
molecule depends entirely on the function it is designed to carry out. Internal pockets 
near the core of the dendrimer can provide microenvironments to contain and protect 
small molecules [99]. In other cases, external charged groups function to tightly bind 
oppositely charged molecules such as DNA or oligonucleotides via electrostatic 
interactions. The amine-terminated carbosilane dendrimers used in this study possess 
external amines, which have been quaternized to attach an additional methyl group to 
each amine nitrogen. This alkyl substituent occupies the nitrogen’s lone electron pair 
in a covalent bond resulting in a positive charge for the amine. This net positive 
charge located at the periphery of the dendrimer allows it to bind the negatively 
charged phosphate groups of the DNA or RNA backbone. 
The size of dendrimers depends on the structure and, in particular, the number 
of generations that the dendrimers possess. Dendrimers range in size from around 1.5 
nm to 15 nm in diameter. This size range categorizes dendrimers as nanoparticles and 
allows them to imitate proteins in terms of their interactions with small molecules or 
other macromolecules [102]. Figure 17 shows how dendrimers can approximate 
protein structures and other bioassemblies in size. This characteristic is essential for 
these synthetic molecules to achieve functions based on biological interactions. Such 
functions include imaging probes, vaccine adjuvants, and the encapsulation, delivery 
and/or controlled release of pharmaceuticals [103-105].  
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Figure 17. Dimensionally scaled comparison of PAMAM dendrimers of several different 
generations with proteins and other bioassemblies. (Source: Esfand, et al. (2001)) 
 In addition to their size, dendrimers benefit from their unique structural 
characteristics in order to function as biologically useful molecules. As with a tree, 
which optimizes the quantity of solar light it can harvest and the amount of moisture 
in the soil it can absorb through the use of dendritic architecture to spread out its 
branches, leaves, and roots, dendrimers make use of this structural characteristic to 
optimize their biological interactions at a molecular level (Figure 18) [106]. 
Furthermore, the highly branched nature of the structure results in a high density of 
functional groups at the molecular surface. This attribute, in addition to maximizing 
the efficiency of the dendrimer in forming molecular interactions, could also theo-
retically allow for the utilization of several different types of peripheral groups on the 
same molecule in order to achieve multiple functionalities. A possible example would 
be dendrimers with cell targeting moieties as well as cationic functional groups to 
bind oligonucleotides and achieve cell specific delivery. 
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Figure 18. Dendritic architecture exists in the branches and roots of trees. (Source: Boas, et al. 
(2006)) 
1.4 Creation of an effective combination 
Dendrimers and cationic polymers represent only some of the nanoparticles 
being utilized today for research in biomedical fields such as drug delivery. The aim 
of this study was to harness the molecular capabilities of these particles, and use them 
in conjunction with RNAi, a relatively new and powerful tool for the manipulation of 
gene expression at the cellular level. HIV infection, one of the most important and 
deadly infectious disease pandemics that affect the world today, was chosen as a 
target for this research. Specifically, complexes consisting of siRNA and dendrimers 
or polymers were utilized therapeutically on the hard-to-transfect CD4+ T lympho-
cytes that constitute the primary cell population susceptible to infection with HIV. 
Additionally, astrocytes were tested as a secondary cell model for HIV infection. The 
results should lead to further understanding in the dynamics of nanoparticle and 
siRNA complexation, the biocompatibility of such complexes, and their capabilities at 
achieving cell transfection and successful gene downregulation. 
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The toll taken by the HIV pandemic on the global human population has been 
immense. The importance in developing therapeutic strategies against this disease has 
allowed for a huge amount of research into the molecular biology of the virus and the 
human immunological characteristics of infection. A large amount of the current 
scientific knowledge of cell biology has arisen as a result of this research. 
RNAi has emerged as a powerful molecular biology tool for the specific 
downregulation of genes, which is being expanded to clinical applications, as well. 
Meanwhile, nanoscopic synthetic polymer structures are increasingly being applied to 
the field of biomedicine. Drug delivery applications by nanoparticles have the 
potential of creating effective pharmaceuticals. By combining RNAi with 
nanotechnology in the form of siRNA-delivering polymers and dendrimers, a whole 
realm of therapeutic applications arise.  
Specifically, the difficulty in transfecting HIV-susceptible lymphocytes and 
reaching the CNS with pharmaceuticals offers the opportunity of applying this novel 
drug delivery system to the challenge of inhibiting HIV replication. 
 
 With this in mind, the specific objectives of this work were: 
 
1. To determine the feasibility of second-generation amine-terminated carbo-
silane dendrimers and polyethyleneimine-graft-poly(ethylene glycol) block 
copolymers as suitable drug delivery vectors for siRNA in terms of the 
structural characteristics and dynamics of the complexes they form. 
 
2. To assay the biocompatibility and cytotoxicity of the dendrimers and polymers 
when used to deliver siRNA to various cell lines and primary cells in vitro. 
 
3. To detect and analyze the cell transfection efficiency, uptake dynamics, and 
capabilities at crossing biological barriers for the dendriplexes and polyplexes. 
 
4.  To measure the biological activity of siRNA delivered to the target cells by 
the dendrimers and polymers at silencing targeted genes and, especially, 
reducing the replication of HIV.  
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3.1 Reagents 
3.1.1 Dendrimers   
Carbosilane dendrimers (CBS) were all synthesized by the group “Química de 
Metalodendrímeros” of the Inorganic Chemistry Department of the Universidad de 
Alcalá de Henares as has been previously reported [107]. The method of preparation 
of the dendrimers follows a divergent procedure (synthesis from the core outwards). 
This method allows for more flexibility in deciding the final product. As the 
dendrimer is synthesized from the core outward, each successive generation results in 
a fork at the exterior point of all the branches and results in a doubling of the total 
number of exterior branches. The number of exterior branches can be described by the 
equation: 
R = 2n+1, 
where R is the total number of exterior branches and n is the dendrimer generation. 
By controlling the generation of the dendrimer, the length and number of branches as 
well as the size and density of the molecule can be controlled. This method of 
synthesis also allows many options for the functional groups at the extremities [108].  
The dendrimers in this work possess two specific characteristics that make 
them suitable for our application. First, they have a silicon-oxygen bond in each of the 
branches. This allows for a time-controlled degradation. Second, the dendrimers 
possess external amine groups that can be quaternized to provide positively charged 
functional groups at the extremities [107, 109]. The resulting positive charge of the 
external amine groups is utilized for the formation of electrostatic interactions with 
the negatively charged backbone of oligonucleotides. 
The degradation of the dendrimer structure occurs via the gradual hydrolysis 
of the Si–O bonds when the dendrimers are exposed to water. For this reason, all 
procedures during synthesis was carried out under the protective conditions of an 
argon atmosphere using standard Schlenk techniques or an argon-filled glove box, 
and all reactants and products were carefully protected from exposure to the 
environment right up until the initiation of the experiments. Once the dendrimers are 
dissolved in an aqueous solution, the slow hydrolysis of the Si–O bond gradually 
releases the external end of each branch from the dendrimer core thus resulting in the 
liberation of the cargo that is bound to the functional groups at the far extremities of 
the dendrimer. 
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In this work, two distinct dendrimers were used. They are 2G-CBS-(OCH2-
H2NMe CH2CH2N+Me3+I-)8  and  2G-CBS-(OCH2CH2N+Me2CH2CH2N+Me3I-)8,  and 
will be referred to as 2G-NN8 and 2G-NN16, respectively, based on the number of 
positive charges each one possesses (Figure 19). The difference between the two 
dendrimers is the degree of quaternization of the exterior amine groups on each 
branch. At pH 7.4 (physiological pH), the two dendrimer variants possess 8 and 16 
positive charges as has been shown by 1H nuclear magnetic resonance (NMR) and 13C 
NMR spectroscopy measurements [107]. 
 
Figure 19. Structure of generation two amine-terminated carbosilane dendrimers, 2G-NN8 and 
2G-NN16. 
3.1.2 Polyethyleneimine-graft-poly(ethylene glycol) Block Copolymers   
 Block copolymers were prepared by grafting linear PEG onto branched PEI. 
In addition to four copolymers, the core PEI polymer (molecular weight (MW): 25 
kDa) with no attached PEG moiety was also tested. The four copolymers used 
consisted of the 25 kDa PEI core grafted with a varying number of PEG chains of 
different molecular weights so that the PEI/PEG ratio was as close to 1 as possible. 
The nomenclature used for naming the polymers designates the MW of the polymer in 
parentheses and uses a subscript to refer to the number of PEG chains and the degree 
Weber, N. 
 
 
 
42 
of grafting so that the copolymer termed PEI(25k)-PEG(2k)10 possesses ten PEG 
moieties of 2 kDa each, and the copolymer termed PEI(25k)-PEG(20k)1 possesses 
one PEG moiety of 20 kDa. The four copolymers were analyzed by NMR to 
determine PEI content, which is shown in (Table 2). To couple the PEG moieties to the 
PEI polymers, a two-step reaction was performed with hexamethylene diisocyanate 
consisting of activation of the monomethyl-PEGs and coupling of the PEGs with PEI. 
This resulted in a water-soluble copolymer containing hydrolytically stable urethane 
and urea bonds. Spectroscopic testing (NMR and FTIR) was used to verify the 
molecular structure of the copolymer products [110]. 
Table 2. Formulas, PEI and PEG content, and structure of copolymers utilized in this study. 
(Derived from figures provided by Merkel O and Kissel T in collaboration with this work)  
 
 
3.1.3 siRNA   
All anti-HIV siRNA sequences were chosen from previously published results 
[53] [57] and [67] and had inhibited HIV replication in experiments using transiently 
transfected cells. All siRNA were purchased from Dharmacon, Inc. (Lafayette, CO). 
The sequences of the various siRNA were siP24, sense: GAU UGU ACU GAG AGA 
CAG GCU, antisense: CCU GUC UCU CAG UAC AAU CUU; siGAG1, sense: GAG 
AAC CAA GGG GAA GUG ACA dTdT, antisense: UGU CAC UUC CCC UUG 
GUU CUC dTdT; siNEF, sense: GUG CCU GGC UAG AAG CAC AdTdT, 
antisense: UGU GCU UCU AGC CAG GCA CdTdT; siGL3, sense: CUU ACG CUG 
AGU ACU UCG AdTdT, antisense: UCG AAG UAC UCA GCG UAA GdTdT. The 
siRNA siP24 labeled with the fluorochrome cyanine 3 (Cy3) or fluorescein 
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isothiocyanate (FITC) on the 5’ end of the sense strand was utilized to detect the 
entrance of siRNA into cells. A positive control siRNA designed to silence the 
expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (siGAPDH) was used to indicate successful transfection and biological 
activity of siRNA. In siRNA functionality experiments a siRNA of random sequence 
was used as a negative control to test for sequence-specific effects (siRandom). This 
siRNA was siCONTROL Non-Targeting siRNA #2 designed and screened by 
Dharmacon to have no silencing effect on any human, mouse or rat genes. The 
sequences and molecular weights for the siRNA are contained in Table 3. 
Table 3. Sequences and molecular weights of siRNA utilized in this work. 
 
3.2 Cells 
3.2.1 Cell Lines  
3.2.1.1 SupT1 cells 
The established cell line SupT1 (human leukemia T-lymphocytes), obtained 
from American Type Culture Collection (ATCC) (Manassas, VA) (cat. CRL-1942) 
was maintained in complete RPMI 1640 growth medium (Biochrom AG) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2mM L-
glutamine, 1% ampicillin, 1% cloxacillin, 0.32% gentamicin, 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1mM sodium pyruvate and 
4.5 g/L glucose at 37°C in a 5% CO2 atmosphere.  
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3.2.1.2 U87MG cells  
The human glioblastoma-astrocytoma epithelial-like cell line U87MG (ATCC 
HTB-14) was routinely grown in Dulbleco’s Modified Eagle Medium (DMEM) 
(Gibco) containing 10% FBS, 1% penicillin/streptomycin, and 2 mM L-glutamine at 
37°C in a humidified atmosphere of 5% CO2. 
 
3.2.1.3 L929 mouse fibroblasts  
The murine fibroblast cell line L929 (ATCC CCL-1) was routinely grown in 
DMEM (Gibco) containing 10% FBS, 1% penicillin/streptomycin, and 2 mM L-
glutamine at 37°C in a humidified atmosphere of 5% CO2. 
 
3.2.1.4 Human Endometrial Carcinoma cells (HEC-1A)  
These human endometrial cells  (ATCC HTB-112) were derived from a 
human endometrial adenocarcinoma. HEC-1A were grown in RPMI medium (Gibco) 
supplemented with 10% FBS, 2mM L-glutamine, 1% cloxacillin, 1% ampicillin and 
0.32% gentamicin in 12 well polycarbonate transwell permeable supports containing 
0.4 µm pores (Costar, Cambridge, MA) at 37°C in a humidified atmosphere of 5% 
CO2. 
 
3.2.1.5 Bovine Brain Microvascular Endothelial cells (bMVEC-B)  
 bMVEC-B cells (Lonza, Walkersville, MD, USA) were grown in EBM-2 
Basal medium supplemented with platelet-poor horse serum, ascorbic acid, β-ECGF, 
heparin and penicillin /streptomycin/fungizone on the same type of 0.4 µm pore poly-
carbonate transwell permeable support coated with rat tail collagen type I (10 µg/cm2) 
(Sigma, Missouri, USA) and coated over with fibronectin (5 µg/cm2) (Sigma, 
Missouri, USA). Complete EBM-2 medium was changed 48–72 hours after seeding 
and every other day thereafter during 11 days to obtain a confluent barrier. 
 
3.2.2 Primary Cell Cultures   
3.2.2.1 Peripheral Blood Mononuclear Cells (PBMC)  
PBMC were obtained from healthy HIV-negative blood donors by standard 
Ficoll-Hypaque density centrifugation, activated with the mitogen 
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phytohemagglutinin (PHA) (2 µg/ml), and maintained in RPMI 1640 complete 
growth medium supplemented with 10% FBS, L-glutamine and antibiotics along with 
interleukin-2 (IL-2) (20 U/ml). 
 
3.2.2.2 Normal human astrocytes (NHA) 
NHA that were isolated from the cerebrum of 5-month-old human fetuses 
were purchased from Cambrex (CC-2565, Walkersville, MD, USA). NHA cells were 
cultured by plating the cells at a density of 15×103 cells/cm2 in expansion media 
(AGM Bullet Kit media, Cambrex) according to the manufacturer's protocol. The 
cells were incubated at 37 °C with 5% humidified CO2 and allowed to reach about 
95% confluence. After this, they were harvested using 0.25% trypsin and 1 mm 
Ethylenediaminetetraacetic Acid (EDTA) for 5 min at 37 °C. 
 
3.2.2.3 Erythrocytes  
Erythrocytes were obtained from donor blood that had been centrifuged in 
Ficoll-Hypaque gradient to separate them from PBMCs. The cells were diluted in 500 
µl phosphate buffered saline (PBS) and seeded in 24 well plates (3×105 cells/well) 
and were immediately treated according to the experimental protocol. 
 
3.3 Virus stocks 
3.3.1 HIV-1 NL4-3   
The X4-HIV virus strain NL4-3 was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from Dr. 
Malcolm Martin [111]. NL4-3 was successfully grown by infecting 1 – 2 ×106 MT-2 
T cells at 1 multiplicity of infection (MOI) in 2 ml medium for 2 hours with regular 
mixing. These cells were then brought up to 6 ml and stored in an upright 25 ml flask 
until 80 – 90% of the cells had formed syncitia at which point the cells were added to 
15 ×106 more cells in a total volume of 15 ml. At 80 – 90% syncitia, the cells were 
collected and spun and the supernatant was stored at -80°C. 
Cell supernatant was titrated for HIV by adding serial dilutions (50 µl) to 2 – 3 
×104 MT-2 cells/150µl in 96 well plates and detecting syncitia formation up until 
seven days. The virus concentration was calculated according to the equation: 
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log DI50 = n – 0.5 + ∑Ri/ni 
 
with DI50 being the viral content in 50 µl; n = the greatest serial dilution with syncitia 
detection in all wells; Ri/ni = the number of syncitia positive wells divided by the total 
number of wells for all further dilutions. 
 
3.3.2 HIV-1 Ba-L  
This R5-HIV virus strain Ba-L was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 Ba-L from Dr. 
Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert Gallo [112]. The R5-tropic 
HIV strain was grown in normal PBMCs. 
 
3.4 Dendriplexes 
3.4.1 Dendriplex formation  
Dendriplexes were formed by mixing equal volumes of dendrimer and siRNA 
dissolved in OPTIMEM® I free of serum or antibiotics at concentrations depending on 
the +/- charge ratio and molar concentration desired according to the formula,   
! 
DNN16 =
P
"
N
+
#MsiRNA # r+ "  
where DNN16 is the molar quantity of dendrimer, 
! 
P
" is the number of nucleotides in 
the siRNA duplex, 
! 
N
+  is the number of quaternized amines in the dendrimer (which 
also represents the molar charge of the dendrimer), MsiRNA is the molar quantity of 
siRNA, and r+/- is the +/- charge ratio (dendrimer to siRNA). As with polyplex 
formation, the molar siRNA quantity and +/- charge ratio were based on the 
experiment to be carried out. In the majority of the experiments, 2G-NN16 was used, 
which offers 16 quaternized amines (
! 
N
+  = 16), and the siRNA possessed 42 
negatively charged phosphates (
! 
P
" = 42). Substituting these values into the equation 
above leaves,  
! 
DNN16 = 2.625 "MsiRNA " r+ #  
This implies that for every mole of siRNA, 2.625 times the +/- ratio number of moles 
of dendrimer was needed to form the dendriplex. The dendriplex mixture was left to 
incubate 15 to 20 min prior to proceeding with experimentation with the dendriplex. 
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3.4.2 Gel Electrophoresis (GE)  
In order to visualize complexation, dendriplexes were run on 3% agarose gels 
containing 0.017% ethidium bromide at 90V for 30min. The gels were photographed 
using a Molecular Imager Gel Doc and Chemi Doc System (BioRad) and the siRNA 
bands that had migrated in the gel were quantified using Quantity One 1D Analysis 
Software. For experiments on the gradual liberation of siRNA from dendriplexes, at 
each time point the total quantity of siRNA that had been initially complexed with the 
dendrimer was compared to the siRNA that had been liberated. This was 
accomplished by splitting the dendriplex samples evenly into two aliquots. One 
aliquot was treated with heparin (2 U/µg siRNA) to free any remaining siRNA from 
complexation with the dendrimer. The difference in intensities of the bands from the 
two aliquots indicated the amount of siRNA retained in the dendriplex. 
 
3.4.3 Strength of Union  
Heparin exclusion experiments were utilized to test the strength of the union 
between dendrimer and siRNA. These were carried out by mixing dendriplexes (+/- 
ratio 4) of 2G-NN8 or 2G-NN16 with varying concentrations of Heparin (0.1, 0.15, 
0.2, 0.3, and 0.6 IU/µg siRNA). The mixture was run on a 20% polyacrylamide gel 
for 2 h at 15 mA that was then immersed in a 0.0017% ethidium bromide solution for 
5 min followed by a 5 min wash in water. The gels were photographed and the bands 
were quantified using the program ImageJ (1.38x, NIH, USA). 
 
3.4.4 Size and zeta potential  
Size and zeta potential measurements on dendrimers were carried out by 
Dzmitry Shcharbin, Elżbieta Pędziwiatr, and Maria Bryszewska from the Department 
of General Biophysics, University of Lodz, Poland. All dendriplex samples intended 
for dynamic light scattering analyses were prepared at 25°C using 0.15 mol/l HEPES 
buffer (containing 6 mmol/l HEPES and 144 mmol/l NaCl), pH 7.4, which was 
filtered with a 0.22-mm filter to remove any trace particulates. Complexes of 2G-
NN16 and siGAG1 were prepared at a 500 nM siRNA concentration and at +/- charge 
ratios between 0 and 16. Particle size of complexes was measured by dynamic light 
scattering (DLS) using a Malvern Zeta-Sizer Nano S90 (Malvern, UK). The light 
scattered at 90° from the incident light was fit to an autocorrelation function using the 
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method of cumulants. The particle size of a sample was determined from the average 
of 12 cycles in a Malvern disposable plastic cuvette at 25oC. 
Zeta potential experiments were carried out by phase analysis light scattering 
(PALS) using a Malvern Instruments Zetasizer 2000 (Malvern, UK) at 25oC. The 
electrophoretic mobility of the scattering (DLS) samples was determined from the 
average of 6 cycles of an applied electric field in a standard rectangular quartz cell. 
The zeta potential of complexes was determined from the electrophoretic mobility by 
means of the Smoluchowski approximation. All data are expressed as a mean value ± 
SEM of 4 independent experiments. Statistical significance was assessed using 
Student-Fisher test.  
 
3.4.5 Nuclear magnetic resonance (NMR)  
1H-NMR spectra were recorded with Varian Unity VXR-300 and Varian 500 
Plus Instruments. Chemical shifts (δ, ppm) were measured relative to residual 1H 
resonances for chloroform-d1 and dimethyl sulfoxide-d6, which were used as 
solvents. NMR spectra experiments were carried out by Paula Ortega and the 
Inorganic Chemistry Department at the Universidad de Alcalá, Spain. Spectra were 
taken at various time points after CBS dendrimers similar to 2G-NN8 and 2G-NN16 
were dissolved in deuterated water. These other dendrimers, which possess only a 
single amine group on each branch outside of the Si–O bonds, were tested in order to 
provide an approximation of how the internal Si–O bonds behave, and because 
equivalent NMR results could not be obtained for 2G-NN8 or 2G-NN16, as the 
additional functional groups of the extra ethylamines located further outside of the 
branch peripheries contribute additional resonance peaks making interpretation of the 
NMR chemical shift graph much more complicated. The results highlighted the 
gradual hydrolysis over time of the Si–O bond of the branches of the dendrimers, 
which can be assumed to be the case for 2G-NN8 and 2G-NN16 because of the 
structural similarities between the types of CBS dendrimers.  
 
3.4.6 Protection from RNase digestion 
For protective effect experiments, dendriplexes (+/- ratio of 2) or siRNA alone 
were incubated with 0.25% RNase (Promega, Madison WI, USA) at 37ºC for 30 min 
and were then loaded on a 3% agarose gel containing 0.017% ethidium bromide and 
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run at 90V for 30 min. Additional experiments to quantify the protective effect were 
performed in which dendriplex (+/- ratio 4) or siRNA alone were treated with RNase 
as before, incubated at 70ºC for 30 min to inactivate the RNase, and treated with 
heparin (2 IU/µg siRNA) to liberate the siRNA from the dendrimer in order to 
quantify it after being run on a 3% agarose gel. 
 
3.5 Polyplexes 
3.5.1 Polyplex formation  
Complexes of siRNA and polymers were formed by mixing equal volumes of 
siRNA and polymer. The necessary quantity of siRNA was diluted with OPTIMEM® 
I medium free of serum or antibiotics at concentrations depending on the molar 
concentration desired. The according amount of polymer was added to the siRNA 
solution depending on the N/P ratio, or the number of polymer nitrogen atoms per 
nucleotide phosphate, according to the equation,  
! 
npolymer =
43.1
g
mol•charge
%PEI content 100%
"P# "MsiRNA " rN P 
where npolymer is the mass of the polymer in grams, %PEI content is the percentage 
content of PEI in the polymer, 
! 
P
"is the number of nucleotides in the siRNA duplex, 
MsiRNA is the molar quantity of siRNA, and rN/P is the ratio of polymer amines to 
siRNA phosphates (referred to as the N/P ratio). The N/P ratio is similar to the +/- 
ratio for dendriplexes since a large percentage of polymer amines are positively 
charged and bind the negatively charged phosphate-sugar backbone of the siRNA 
according to the ratio of amine nitrogen atoms to phosphates. This ratio along with the 
molar siRNA quantity was assigned values depending on each experiment. A higher 
N/P ratio would be used in order to ensure total complexation with the siRNA and a 
better transfection efficiency, while the N/P ratio would be decreased in order to 
improve biocompatibility by minimizing the quantity of polymer necessary to 
transfect the desired amount of siRNA. 
After mixing siRNA and polymer together, polyplexes were incubated for 20 
min. The optimal incubation time was determined by dynamic light scattering. 
Complex formation attributes such as complexation and condensation of siRNA was 
investigated by gel retardation assays. 
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3.5.2 Gel Electrophoresis 
For gel retardation assays, non-denaturing 20 % polyacrylamide gels (PAGE) 
were composed of 15 ml Rotiphorese Gel 40 solution, (Carl Roth GmbH, Karlsruhe, 
Germany), 3 ml 10× TBE buffer, 12 ml double-distilled, DEPC-treated water, 150 µl 
10 % APS (Carl Roth GmbH, Karlsruhe, Germany), and 30 µl TEMED (Carl Roth 
GmbH, Karlsruhe, Germany). Gels were used freshly after polymerization to avoid 
RNase contamination and loaded with free siRNA as control (C) and complexed 
siRNA with increasing N/P ratio in a total volume of 10 µl per slot. Gels were run in 
1 x TBE buffer for 1 h at a maximum of 100 V and 15 mA per gel followed by 
bathing in a 0.0017 % ethidium bromide solution in 1× TBE buffer. 
 
3.5.3 Size and zeta potential  
All size and zeta potential measurements of polymers were carried out by 
Olivia Merkel and the Department of Pharmaceutics and Biopharmacy, Philipps 
Universität Marburg, Germany lead by Dr. Thomas Kissel. For dynamic light 
scattering, 50 pmol siRNA per measurement were mixed with the according amount 
of polymer for an N/P ratio of 10 in a total volume of 50 µl. Following the 20 min 
incubation, the polyplex was diluted in 5% glucose at pH 7.4 to give a total volume of 
500 µl. Measurements were performed using a Zetasizer Nano ZS from Malvern 
Instruments (Herrenberg, Germany) equipped with a 10 mW HeNe laser at a 
wavelength of 633 nm at 25°C and analyzed in CONTIN mode. The instrument was 
checked periodically with Nanosphere Size Standards (polymer microspheres in 
water, 199 nm ± 6nm) from Duke Scientific (Palo Alto, CA). For data analysis, the 
viscosity and refractive index of water at 25°C (0.89 mPa·s and 1.333, respectively) 
were used. The measurements were performed in triplicate. Neither the position nor 
attenuator were fixed but were optimized by the device. For the optimization 
experiments, long-term measurement of sizes was recorded over roughly one hour. 
The zeta potentials (surface charge) of freshly prepared polyplexes were determined 
using the standard capillary electrophoresis cell of Zetasizer Nano ZS from Malvern 
Instrument at 25°C. Average values were calculated with the data of 10 runs with 
standard deviation. 
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3.6 Cytotoxicity   
3.6.1 Lactase dehydrogenase (LDH) assay   
3.6.1.1 Lymphocytes 
To test cytotoxicity, cells were submitted to treatment of dendrimers, 
dendriplexes, polymers or polyplexes and toxic effects were assessed by measuring 
cell membrane rupture and release of LDH into the supernatant via the CytoTox96® 
Non-Radioactive Cytotoxicity Assay kit (Promega). In all experiments, the 
transfection medium, whether it is dendrimer, dendriplex, polymer, polyplex or 
Lipofectin®, was never removed prior to the end of the experiment.  SupT1 cells were 
seeded 24 h prior to treatment in 96 well plates in complete medium (1.5×105 cells in 
190 µl/well) and were submitted to treatment (10 µl) of 2G-NN16 alone or complexed 
with siRNA at varying +/- charge ratios. Three to 24 h later, 100 µl of the cells were 
extracted, spun at 1500 rpm for 5 min, the supernatant was separated and the cells 
were put aside to be run through the flow cytometer. The supernatant was analyzed 
for LDH according to kit protocol. Measurements were reported in relation to a 
positive control for cell death (TritonX-100 (0.1% w/v)) after subtracting the 
background as determined by untreated control cells. The values were calculated 
according to the following formula: 
! 
Cytotoxicity(%) =
X -C
Tr - C
"100  
where X represents the color intensity of each sample, C is the background (untreated 
cells), and Tr is the positive control (TritonX-100).  All points were performed in 
triplicate. A toxicity limit was set at 10% LDH release [113]. Experiments with 
polymers and polyplexes at varying N/P ratios were also carried out utilizing the same 
protocol except only measuring results at 3 h. 
 
3.6.1.2 Astrocytes 
 U87MG astrocytes were seeded the day prior to treatment in 96 well plates in 
complete medium (5×104 cells in 200 µl/well). After allowing the cells to attach to the 
well bottoms, treatments of varying concentrations of dendrimer were added to the 
wells. Supernatant samples were taken at 3, 5 and 24 h and measured for the presence 
of LDH indicating membrane rupture as before.  
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3.6.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) Assay 
3.6.2.1 Lymphocytes 
SupT1 or PBMC were seeded in 96 well plates in OPTIMEM® I medium 
containing 10% FBS (1.5×105 cells in 190 µl/well) and submitted to 10 µl treatment 
of siRNA alone or complexed with 2G-NN16 at varying +/- charge ratios. Twenty h 
later, 20 µl of MTT substrate solution (5 mg/ml) was added to the cells to measure 
mitochondrial activity. After 4 h, the supernatant was removed and the formed 
crystals were dissolved in 200 µl DMSO and absorbance was measured in a plate 
reader (Biowhittaker microplate reader 2001, Innogenetics) at 550 nm with a 
reference of 690 nm. All points were performed in triplicate. 
 
3.6.2.2 Astrocytes 
U87MG or NHA were seeded the day prior to treatment in 96 well plates in 
complete medium (5×104 cells in 200 µl/well). After allowing the cells to attach to the 
well bottoms, treatments of varying concentrations of dendrimer were added to the 
wells. After 3, 5, 24 or 72 h, the medium was removed and replaced with 200µl 
OPTIMEM® I medium containing MTT substrate solution (0.5 mg/ml) and 
mitochondrial activity was measured as before. 
 
3.6.2.3 L929 fibroblasts 
Cytotoxicity of PEI-PEG copolymers was tested on L929 cells via MTT 
assays by Olivia Merkel and the Department of Pharmaceutics and Biopharmacy, 
Philipps Universität Marburg lead by Dr. Thomas Kissel. Briefly, L929 cells were 
seeded in 96 well plates (8×103 cells in 200 µl/well) 24 h prior to the experiment. 
Polymer solutions were prepared in serum-free DMEM medium. In each well, 100µl 
of polymer solution was mixed with 100 µl of full serum containing medium. Cells 
were incubated with polymer treatments for 24 h, and then, the medium was replaced 
with 200 µl DMEM containing MTT substrate solution (0.5 mg/ml) and 
mitochondrial activity was measured as before. 
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3.6.3 Cell Proliferation   
SupT1 were seeded in 96 well plates 24 h prior in complete medium 
containing 2% FBS (1×105 cells in 100 µl/well). The following day, the serum was 
brought up to 10% and the cells were submitted to treatment with siRNA alone or 
dendriplex. After 20 h and 48 h, cell proliferation was measured by detecting the 
incorporation of bromodeoxyuridine (BrdU) in newly synthesized DNA according to 
kit protocol (Chemicon International, Temecula, CA, USA). Experiments following 
the same protocol were also carried out with U87MG cells. 
 
3.6.4 Absolute Cell Numbers   
SupT1 cells were seeded and submitted to treatment the same as for LDH 
experiments with mock treatment and TritonX-100 used as controls. The commercial 
cationic lipid reagent Lipofectin® (Invitrogen, Calsbad, CA, USA) was used as a 
comparative control according to kit transfection protocol for cells in suspension. 
Seventy-two h later, healthy and viable cells were counted from 10 µl samples from 
each well using a Neubauer slide under a light microscope. 
 
3.6.5 Hemolytic Activity and Erythrocyte Aggregation  
The hemolytic activity and erythrocyte aggregation caused by treatment of 
dendrimers, dendriplexes or polymers on human erythrocytes was investigated to 
measure the cytotoxic effects of these macromolecules on red blood cells, the most 
numerous type of blood cell [114, 115]. For experiments with dendrimers or 
dendriplexes, erythrocytes were diluted in 500 µl PBS and seeded in 24 well plates 
(3×105 cells/well) [116]. As a positive control, cells were treated with Triton X-100 at 
0.2%, and PBS was used as a negative control. Erythrocytes were then treated with 
different concentrations of dendrimer and dendriplex. After 1 hour of incubation, 100 
µl of supernatant was obtained for evaluation of the hemoglutination, cell number and 
hemoglobin release levels by the plate reader spectrophotometer at a wavelength of 
550 nm using 690 nm as a reference.  
 For experiments with polyplexes, the red blood cells were washed in HEPES-
buffered saline (HBS) until the supernatant was clear and colorless and were then 
diluted with HBS to 5×108 cells/ml. Polyplexes were prepared at an N/P ratio of 10 in 
a total volume of 125 µl  (7.5 µM siRNA). One percent Triton X-100 in HBS (100% 
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lysis) and pure HBS (0% lysis) were used as controls. Forty microliter aliquots of 
polyplex solutions were mixed with 40 µl erythrocyte suspensions. Samples were 
incubated for 30 min at 37 °C under constant shaking. After centrifugation at 850×g, 
supernatant was analyzed for hemoglobin release at 541 nm (Ultrospec 3000, GE 
Healthcare, Munich, Germany). The pellet was resuspended with 50 µl HBS and used 
for monitoring of erythrocyte aggregation. For quantification of hemoglobin released 
by cells treated with polyplexes, a UV spectrum of a 1:1 dilution of Triton X-100 
lysed erythrocytes revealed maxima at 541 nm and 576 nm. All samples were 
measured in triplicate. 
 
3.6.6 Microarrays  
Astrocytoma cells were spread in a P6-culture plate at a density of 8×105 
cells/well and cultured overnight. Then cells were incubated with 2G-NN16 (24 
µg/ml) for 3 or 5 h. Finally, U87MG were detached mechanically, rinsed in PBS, and 
centrifuged. RNA was extracted using RiboPure-Kit (Ambion) following the kit 
protocol. RNA was measured in a Nanodrop® ND-1000-UV/Vis Spectrophotometer 
and RNA integrity was verified using a 2100 Bioanalyzer (Agilent). For each 1 µg 
sample of total RNA was amplified and labeled using Low RNA Amplification plus 
Kit One Color (Agilent) following the manufacturer’s instructions. Briefly, RNA was 
denatured and reverse transcribed to cDNA. This cDNA was then transcribed in vitro 
to RNA using T7 RNA polymerase. Amplified RNA was cleaned up using RNeasy 
MiniKit (Quiagen). Antisense RNA quantification was performed with the Nanodrop® 
Spectrophotometer and verification of the antisense RNA integrity in the Agilent 
Bioanalyzer. Hybridization and scanning of microarrays were performed as specified 
in “One-color microarray-based gene expression analysis” v5.0.1 using all reagents 
recommended by Agilent and 4×44K whole genome human microarrays (Agilent 
Technologies). These microarrays contained more than 40,000 oligonucleotides 
representing human transcripts and more than 3,000 control spots. Slides were 
scanned using a G2565BA Agilent-scanner and data was obtained by 
FeatureExtraction v9.1. The open software Bioconductor was used for normalization 
and statistical analysis. 
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3.7 Transfection efficiency 
3.7.1 Flow Cytometry   
At different time points following treatment with dendriplexes, polyplexes, 
dendrimers, or siRNA alone (at varying concentrations, N/P ratios or +/- charge 
ratios), cells were analyzed by flow cytometry to determine two attributes, 1) the 
percentage of the cell population that could be deemed viable, and 2) the percentage 
of the viable cell population that exhibited fluorescence representing successful 
uptake of the Cy3-labeled siRNA (siRNA, dendriplex, and polyplex treated cells 
only). Cells were washed with either trypsin or glycinic acid to remove any siRNA 
from the membrane exterior. When cells washed with acid produced identical results 
as non-washed cells, this step was occasionally omitted in order to maintain high cell 
retention. 
 Following treatment with siRNA alone or dendriplexes, U87MG cells were 
likewise analyzed by flow cytometry to determine the transfection efficiency of Cy3-
labeled siRNA in the viable cell population. We also studied the transfection intensity 
at 3 hours, by x-mean values. Cells were washed with glycinic acid to remove any 
siRNA on the membrane exterior.  
 
3.7.2 Confocal Microscopy 
SupT1 cells that had been treated with Cy3-labeled siRNA alone, in 
dendriplex or with a mock treatment were collected after 20 h incubation spun and 
resuspended in OPTIMEM® I medium. Cell membranes were labeled by incubating 
the cells with a 1:20 dilution of anti-CD45-FITC antibody (Beckman Coulter, 
Fullerton, CA, USA). Without being fixed, the “in vivo” cells were attached to a slide 
with poly-L-lysine then viewed and photographed with a Leica TCS SP2® confocal 
microscope using different excitation wavelengths (488 and 543 nm). Un-labeled 
photographs were analyzed by three independent viewers to determine percentage of 
cells positive for uptake of siRNA. Videos were made of the live cells by capturing 
still images every 30 s during a 5 min span. 
Polyplex-treated cells were prepared the same as dendriplex-treated cells 
except that they were collected 24 h after treatment and were also labeled with 4'-6-
Diamidino-2-phenylindole (DAPI) (Calbiochem, San Diego, CA) (5 µg/ml) in order 
to detect cell nuclei. The confocal microscope also utilized an excitation wavelength 
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of 405 to view the DAPI-stained nuclei. Unlabeled photographs were analyzed by 
three independent viewers to determine cell viability as well as uptake. 
 
3.7.3 Immunofluorescence Microscopy 
 U87MG cells were seeded on coverslips in 24 well plates 24 h prior to being 
treated with siRNA alone or dendriplexes at +/- ratios of 4 or 8. Twenty-four h later, 
the coverslips were collected, rinsed with PBS, and stained with DAPI (5 µg/ml). The 
coverslips were mounted on microscope slides with DakoCytomation-Fluorescent-
Mounting-Medium (Denmark), and photographed with a Nikon Eclipse E800 
immunofluorescence microscope using filters of 400-420 nm (DAPI) and 575-590 nm 
(Cy3). 
 
3.8 Capability of dendriplexes to pass through biological membranes  
3.8.1 Polarized epithelial cells (HEC-1A) 
To obtain a tight monolayer, HEC-1A were grown in RPMI-1640 medium 
with 10% FCS on a 0.4 µm pore polycarbonate permeable support (Costar, 
Cambridge, MA). Briefly, 2×105 cells were seeded per filter insert and were grown 
for 7 days as described elsewhere [117]. In the basolateral zone of the chamber 
PBMCs that had been activated with PHA (2 µg/ml) and IL-2 (60 IU/ml) were 
cultured in RPMI-1640 medium with 10% FCS. Prior to initiating the experiment, the 
transepithelial electric resistance (TEER) of the monolayer was measured with an 
Epithelial Voltohmmeter (World Precision Instruments), and only when a 
measurement of > 300 Ωcm2 was obtained would the barrier be considered fully 
formed [118].  HEC-1A that were being grown concurrently on coverslips were 
monitored with a light microscope to estimate the growth progress and confluency of 
the cells. Magnified images were taken of naked cells using a Nomarski prism and 
cells dyed with silver nitrate (AgNO3) to label the tight cell junctions. When the 
monolayer was deemed to be 100% confluent, siP24-Fl alone or siP24-Fl/2G-NN16 
dendriplexes were added to the apical zone. Five or 72 h following treatment, the 
PBMCs were collected and analyzed by flow cytometry to determine the percentage 
of viable cell population that exhibited fluorescence representing successful 
transcytosis and subsequent transfection of the fluorochrome-labeled siRNA [119]. 
The HEC-1A that were concurrently grown on coverslips were also submitted to the 
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treatments and monitored by a microscope to detect any cell death or cell detachment 
from the barrier. No negative effects from the treatments that caused the barrier to be 
broken were observed. 
 
3.8.2 Bovine brain microvascular endothelial cells (bMVEC-B) 
 5×105 cells/cm2 of bMVEC-B were seeded in complete EBM-2 basal medium 
on a 0.4 µm pore polycarbonate permeable support coated with rat tail collagen type I 
(10µg/cm2) (Sigma, Missouri, USA) and coated over with fibronectin (5µg/cm2) 
(Sigma, Missouri, USA). Complete EBM-2 medium was changed 48-72 hours after 
seeding and every other day thereafter during 11 days to obtain a confluent barrier. 
Barrier formation was analyzed by measuring the TEER as described above. In the 
basolateral zone of the chamber, activated PBMCs or U87MG cells were cultured in 
the corresponding medium. When the monolayer was formed, siP24-Fl alone or in 
dendriplex was added to the apical zone. Five or 72 h later, the PBMCs or U87MG 
cells were collected and analyzed by flow cytometry as mentioned above.  
 
3.9 Transfection via electroporation 
3.9.1 GAPDH silencing via electroporation of siRNA   
SupT1 cells were washed and resuspended in serum-free OPTIMEM® I 
medium. Either 4×106 or 8×106 cells/point were mixed with siRNA varying in 
concentration from 10 nM to 0.5 µM in OPTIMEM® I at a cell concentration of 
10×106 cells/ml in a cuvette and incubated on ice for 15 min prior to subjecting the 
cuvette to an electropulse (250V, 1050F) (EasyjecT Plus® Multipurpose 
Electroporation System). The cells were left to recover at room temperature for 15 
min before being added dropwise to 2 to 4 ml warm complete medium. Cells were 
harvested from 2 to 6 days after electroporation and the RNA was extracted according 
to the SV Total RNA Isolation System kit protocol (Promega). Total RNA quantities 
were normalized between points by measuring RNA concentrations with a Nanodrop® 
ND-1000-UV/Vis Spectrophotometer. Reverse transcription polymerase chain reac-
tions (PCR) were performed as before [120] using the ImProm-II Reverse 
Transcription System (Promega) and real-time PCR using Brilliant® SYBR® Green 
QPCR Master Mix (Stratagene, Cedar Creek, TX, USA) were performed to quantify 
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GAPDH gene expression at the mRNA level using the housekeeping gene β-actin to 
normalize mRNA quantities. The primers used to amplify the GAPDH gene were 
TGG-GGA-AGG-TGA-AGG-TCG-G (forward) and GGG-ATC-TCG-CTC-CTG-
GAA-G (reverse) (Eurogentec S.A., Belgium) and the primers for β-actin 
amplification were GGC-TTC-CCC-AGT-GTG-ACA-T (forward) and GGG-GTG-
TTG-AAG-GTC-TCA-AA (reverse) and an annealing temperature of 58C was used 
in real-time PCR. 
 
3.9.2 HIV inhibition via electroporation with siRNA  
PBMC that had been stimulated for 2 days with PHA were infected with HIV 
NL4-3 at 0.5 MOI in a total volume of 1 ml during two hours with frequent mixing. 
Three days later, the infected cells were collected and spun (1200 rpm, 10 min) and 
washed once with cell culture medium at room temperature. One million cells/point 
were resuspended in 500 µl OPTIMEM® I (room temperature), mixed with the 
corresponding siRNA treatment, transferred to a cuvette, subjected to an electropulse 
(250V, 1050F), and immediately transferred to 15 ml of warm culture medium. 
Samples of cells and supernatant were collected every 24 h starting 24 h post-
treatment and tested for transfection of siRNA and HIV viral concentration, 
respectively. Transfection of siRNA was detected via flow cytometry, and HIV 
replication was measured by assaying the HIV antigen (Ag) p24 with ELISA kit 
(INNOTEST® HIV Antigen mAb, Innogenetics, N.V., Belgium) according to the kit 
protocol. 
 
3.10 Treatment with dendriplex 
3.10.1 GAPDH silencing 
3.10.1.1 SupT1 
SupT1 cells were seeded in 24 well plates in complete medium (1×106 cells in 
900 µl/well) and were submitted to 100 µl treatment of siGAPDH (500 nM) either 
alone, complexed with 2G-NN16 at a +/- ratio of 2, or with Lipofectin® according to 
manufacturer protocol. Cells were harvested 48 h later and RNA was extracted and 
GAPDH mRNA was quantified by qPCR as mentioned above. 
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3.10.1.2 U87MG 
U87MG cells were seeded in 6 well plates (3×105 cells/well) 24 h prior to 
being treated with siRNA alone, dendriplexes (250 nM siRNA, +/- ratio of 8), or 
dendrimer alone (24 µg/ml). Forty-eight h later, the cells were trypsinized (0.25%) 
and collected, RNA was extracted, and GAPDH mRNA was quantified by qPCR as 
mentioned above. 
 
3.10.2 HIV inhibition 
3.10.2.1 PBMC and SupT1   
PBMC that had been previously stimulated with PHA for up to 3 days or 
SupT1 cells were infected with HIV NL4-3 at 0.05 or 0.01 MOI, respectively. The 
cells were washed twice with warm medium before being plated and treated with 
siRNA or dendriplexes at varying concentrations and +/- ratios. The dendriplex 
treatment was added to the infected cells within an hour of the end of the incubation 
with HIV. The dendriplex was formed in serum- and antibiotic-free OPTIMEM® I 
and incubated 15 min, room temp for the complex to form prior to adding it to the 
plated cells. Samples were collected every 24 h starting 24 h after treatment, spun, 
and the supernatant was collected and assayed for viral concentration using the HIV 
protein p24 ELISA kit according to kit protocol. The dilution factors depended on the 
MOI and the time point in which the sample was collected but ranged from 10–1 to 
10–4. 
 
3.10.2.2 U87MG  
Astrocytoma cells were seeded in 6 well plates in complete medium and 
infected with either the X4-tropic HIV-1 NL4-3 or the R5-tropic HIV-1Ba-L at 1 MOI. 
The cells were washed twice with warm medium and treated with siRNA, dendrimers, 
or dendriplexes at varying concentrations and +/- ratios. Supernatants were collected 
3 days after the initiation of treatment and saved in a -20ºC freezer. Amplicor HIV-1 
Monitor Test was used to determinate HIV-1 RNA in supernatant samples. The test 
was performed according to the manufacturer’s instructions and indicates the quantity 
of genomic viral RNA in the collected supernatants by quantitative polymer chain 
reaction (qPCR). 
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3.11 Treatment with polyplex 
3.11.1 GAPDH silencing  
SupT1 cells were seeded in 24 well plates in complete medium (1×106 cells in 
900 µl/well) and were submitted to 100 µl treatment of siGAPDH (500 nM) either 
alone or complexed with polymers at an N/P ratio of 10 for all polymers possessing 
PEG chains and 5 for PEI(25k). Cells were harvested 48 or 72 h later and RNA was 
extracted and GAPDH mRNA was quantified by qPCR as mentioned above.  
For repetitive treatment experiments, SupT1 cells were seeded in 24 well 
plates in complete medium (1×106 cells in 900 µl/well) and maintained in passage for 
22 days. This was accomplished by collecting samples of 400-500 µl containing cells 
every 2 or 3 days starting 3 days after the initial treatment and replacing the lost 
volume with 400 µl fresh medium and 100 µl of new treatment. Only PEI(25k)-
PEG(2k)10 and PEI(25k)-PEG(20k)1 were tested. The same siRNA concentration and 
N/P ratios were used as before. The samples were centrifuged, and RNA was 
extracted from the cells and tested for GAPDH expression by qPCR as mentioned 
above. 
 
3.11.2 HIV inhibition  
SupT1 cells were seeded in 24 well plates in complete medium (1×106 cells in 
900 µl/well) and were submitted to 100 µl treatment of siNEF, siCOCKTAIL, or 
siRandom (500 nM) either alone or complexed with polymers at an N/P ratio of 10 for 
all polymers possessing PEG chains and 5 for PEI(25k) 16–20 h prior to being 
infected with HIV NL4-3 (100 ng/1×106 cells) for 2 h with mixing every 30 min. The 
cells were then washed two times with warm medium and counted. One hundred 
thousand cells in 200 µl/point were seeded in 96 well plates. Transfection was 
confirmed by flow cytometry. After 72 h, supernatant samples were collected and 
analyzed for viral p24 protein content as described above. 
 Longer-term HIV inhibition experiments were carried out by treating SupT1 
cells with polyplexes (50 µl treatment to 5×105 cells in 450 µl/point) at the same 
siRNA concentrations and N/P ratios as before, infecting them with HIV NL4-3 (as 
explained above, 24 h after treatment), and maintaining them in passage for up to 15 
days (initially 5×105 cells seeded in 1 ml/point). Supernatant samples were taken 
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every 2-3 days by removing 500 µl and centrifuging at 1500 rpm for 5 min to ensure 
only supernatant was collected. On the same day that samples were collected, the 
polyplex treatments were administered again by adding 100 µl polyplex and 400 µl 
fresh complete medium to each point. If the total volume had fallen considerably 
below 1 ml/well, samples of less than 500 µl would be collected so that the total 
volume would return to 1 ml upon the addition of treatments. The antiretroviral 
nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT) (0.5 µM) was 
used as a control for HIV inhibition. 
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4.1 Dendriplex formation and stability  
4.1.1 siRNA/CBS dendriplex complexation 
siRNA/CBS dendriplexes were formed in OPTIMEM® I and tested for 
stability using gel electrophoresis. Three percent agarose gels were used to detect 
retention of the siRNA due to its union with the dendrimer at varying +/- ratios. Full 
retention of the siRNA in the lane wells indicated full complexation and condensation 
of the siRNA by the dendrimer vehicles and the formation of a stable complex. 
Various trials revealed that siRNA retention is seen starting with a +/- ratio of 1 with 
full retention achieved with +/- ratio from 2-4 for both the CBS dendrimers 2G-NN8 
and 2G-NN16. As seen in (Figure 20), dendriplexes formed between siP24-Cy3 and 
2G-NN8 or 2G-NN16 were stable and did not migrate in the gel at +/- ratios of 2, 4, 6 
or 8. The siRNA-dendrimer complex was clearly retained in the gel wells as is 
apparent by the fluorescence emitted by the ethidium bromide stained siRNA 
oligonucleotides in the wells of the gel. 
 
Figure 20. Retention of siP24-Cy3 by 2G-NN8 or 2G-NN16. Numbers indicate +/- charge ratios of 
dendriplex. 
 
4.1.2 Strength of dendriplex union  
To be effective at achieving cell delivery, dendriplexes must possess a union 
of sufficient strength to withstand encounters with other macromolecules during cell 
transfection and intracellular trafficking, but still be able to release the oligonucleotide 
cargo after reaching the cell cytoplasm. In order to test the relative strength of the 
union between siRNA and CBS dendrimer, we measured dissociation behavior of the 
complexes when exposed to heparin, a polyanion possessing a very high charge 
density, which competes with the siRNA for binding the dendrimer. PAGE was 
utilized to adequately visualize and quantify the siRNA released from the dendriplex 
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as the concentration of heparin added to the sample increased. It was found that 2G-
NN8 binds siRNA more strongly, as a slight release of siRNA is not seen until 
heparin concentration reaches 0.2 IU Hep/µg siRNA (Figure 21A), while the release 
of siRNA from 2G-NN16 begins at 0.15 IU/µg (Figure 21B). Moreover, there is a 
substantially larger amount of siRNA released at 0.2 IU/µg with 2G-NN16 (60%) 
than with 2G-NN8 (8%). 
 
Figure 21. Strength of union assay. Competition for binding with dendrimer results in the release and 
migration of siRNA as heparin concentration increases. (A) 2G-NN8, (B) 2G-NN16. Relative 
intensities of the siRNA bands in the gel are shown by the black bars below each lane.  
 
4.1.3 Dendriplex size and zeta potential  
To measure the hydrodynamic particle diameter and zeta potential of 
dendriplexes, DLS was utilized. Addition of 2G-NN16 led to changes of zeta potential 
of siGAG1. From a +/- charge ratio of 1 up to 3, a sharp and significant increase of 
zeta potential from -20 to +5 was observed. When dendrimer concentration was 
increased from a +/- charge ratio of 4 up to 16, a continuous but more gradual 
increase of zeta potential was observed. Based on these data, the dendriplex composed 
of 2G-NN16 and siGAG1, when formed in HEPES buffer, appeared to possess a +/- 
charge ratio of 3 (Figure 22A). The particle size of the dendriplexes estimated by 
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intensity at different NN16/siGAG1 charge ratios is presented in Figure 22B. At a 
charge ratio of between 3 and 8 the size of dendriplexes ranged from 300 to 370 nm. 
Further addition of dendrimer led to an increase in dendriplex size.  
 
Figure 22. Zeta potential and particle size of dendriplex. (A) Zeta potential of 500 nM siGAG1 
upon addition of 2G-NN16 at varying +/- charge ratios. (B) Particle size (estimated by intensity) of the 
same dendriplex formations. Dendriplex formed in 0.15 mM HEPES buffer, pH 7.4, 25ºC. 
4.2 Polyplex formation and stability  
4.2.1 PEI-PEG copolymers/siRNA polyplex complexation  
PEI-PEG/siRNA polyplexes were formed using a similar protocol as 
dendriplexes. Initial studies on siRNA complexation and condensation characteristics 
at varying N/P ratios were carried out via gel electrophoresis. If the ratio of polymer 
to siRNA was sufficient to fully condense the siRNA, the siRNA did not migrate in 
the gel and appeared at or near the lane well. The existence of PEG moieties on the 
polymers had an effect on the polymer’s ability to complex with siRNA, as did the 
size/number of moieties, albeit to a lesser extent. Unmodified PEI was most efficient 
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in complexation and condensation of siP24-Cy3, and at an N/P ratio of 3, siRNA was 
almost fully retained in the gel well and was condensed entirely at an N/P ratio of 5 
where a strong decrease in fluorescence was observed (Figure 23A). The PEG 
modified copolymers were only slightly less efficient at complexing siRNA. For all 
three of the higher grafted copolymers, PEI(25k)-PEG(550)30, PEI(25k)-PEG(2k)10, 
and PEI(25k)-PEG(5k)4, full complexation was achieved at N/P ratios between 6 and 
8 (Figure 23B-D). However, a substantial amount of the siRNA was already partially 
retained at the N/P ratio of 5, as could be seen by the siRNA smear in this lane. 
PEI(25k)-PEG(20k)1 revealed practically the exact same results for siRNA 
complexation as PEI(25k) (Figure 23E). 
 
Figure 23. Complexation and condensation of siP24-CY3 by PEI (25k) (A) and its PEGylated 
versions (B - E). N/P ratio of polyplex samples is indicated above each lane. 
4.2.2 Polyplex size and zeta potential 
As had been done for dendrimers, DLS was used to analyze the particle size 
and zeta potential of polyplexes formed with the different polymers. Figure 24 shows 
results for the five polymers bound to siGL3 at an N/P ratio of 10 [89]. This N/P ratio 
was used because changes in particle size for PEI(25k)-PEG(2k)10/siGL3 were shown 
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to stabilize at an N/P ratio of 10 when increasing the N/P ratio from 5 up to 50 (data 
not shown) [89]. Particle size was directly related to the size of the PEG blocks that a 
polymer had as copolymers with larger PEG blocks formed smaller particles than 
copolymers with smaller PEG blocks. The larger particle size formed by PEI(25k)-
PEG(550)30/siGL3 (300-400 nm) was evidence of less siRNA condensation ability by 
this highly grafted polymer. On the other hand, polymers with less PEG grafting 
formed stable particles of 130-150 nm revealing the possibility that the siRNA can 
interact with the PEI core without interference from the PEG moieties for these 
copolymers, especially for PEI(25k)-PEG(20k)1 which possesses only a single PEG 
moiety and appears to condense the siRNA the most. The copolymers were all stable 
and did not increase in size during an incubation of at least 20 min, while particles of 
siRNA with the homopolymer PEI(25k) increased in size by 35% (data not shown) 
[89]. This indicates that the PEG moieties prevented aggregation via a steric shielding 
effect for polyplexes consisting of the copolymers. 
 
Figure 24. Particle size and zeta potential for polyplexes with siRNA in 5% glucose at N/P ratio 
of 10. (♦) ζ potential; (bar) particle size. *p < 0.05. Borrowed from Mao, et al. (2006) with permission. 
 The surface charge of the polyplexes is shown by the ζ-potential (Figure 24). 
Ungrafted PEI(25k) polyplexes had a high positive charge with a ζ-potential of +22.3 
mV. The copolymers showed reduced ζ-potential values compared to PEI(25k). 
Particles containing PEI(25k)-PEG(550)30 had a full shielding effect by the PEG. The 
other three copolymers exhibited higher ζ-potentials (+15 – 17 mV) with no statistical 
differences among them [89]. 
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4.3 Time-controlled liberation of siRNA from dendriplex  
4.3.1 Gradual hydrolysis of Si–O bonds of dendrimer branches 
The carbosilane dendrimers were designed to undergo a gradual degradation 
via hydrolysis of its internal Si–O bonds when dissolved in an aqueous solution. This 
degradation of the exterior dendrimer branches would result in the liberation of any 
cargo that had been bound to the charged peripheral amines, as the external section of 
the branches would break away from the core. In the case of cargoes such as 
oligonucleotides, siRNA, or plasmids, functionality could only be restored to the 
nucleic acids once they had been released from the dendrimer escort core. Through 
experimentation on the union between CBS dendrimers, including 2G-NN8, and 
antisense oligonucleotides, this liberation of cargo was previously estimated by 
Bermejo, et al. to be between 6 and 24 h [107]. In addition, the structural degradation 
of the branches was demonstrated via NMR [109]. Figure 25 shows proton NMR 
spectroscopy results highlighting the gradual hydrolysis over time of the Si–O bond of 
the branches of a CBS dendrimer similar to 2G-NN8 and 2G-NN16, but possessing 
only a single amine group outside of the Si–O bond. The results indicated that the 
timeframe for hydrolysis was from 1 to 12 hours with total hydrolysis not occurring 
until after 5 h. 
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Figure 25. Proton NMR spectroscopy performed at different time points after dilution in heavy 
water (D2O) shows the gradual hydrolysis of Si–O bonds of an amine-terminated carbosilane 
dendrimer possessing the same core as 2G-NN8 and 2G-NN16. Purple dots indicate peaks 
associated to functional groups of the unhydrolized exterior dendrimer branches, while blue squares 
show peaks for the functional groups of the hydrolysis product.  
4.3.2 Gradual liberation of siRNA from dendriplex 
To determine the kinetics of the interaction between 2G-NN16 CBS 
dendrimers and siRNA and analyze the gradual dendriplex degradation experi-
mentally, samples of dendriplexes were visualized by gel electrophoresis at various 
time points after dendriplex formation. As before, siRNA migration indicated free 
siRNA that had been liberated by the dendrimer, while a lack of siRNA migration 
indicated a stable non-degraded dendriplex. Each sample was split into two fractions, 
and one of the fractions was treated with heparin (2 IU/µg siRNA) to force the 
dissociation of siRNA from the dendrimer and reveal the quantity of siRNA still 
complexed to the dendrimer at each time point. Figure 26A shows the bands of 
liberated siRNA free to migrate in the gel at different time points. For both +/- charge 
ratios of 2 and 4, but particularly at a ratio of 4 (fourth lane), retention of siRNA by 
2G-NN16 can be seen up through 12 h followed by a gradual liberation. Figure 26B 
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shows the graphical analysis of the intensities of the siRNA bands. The percentage of 
siRNA complexed to and retained by 2G-NN16 can be determined by the differences 
between the intensities of the dendriplex bands and the heparin-treated dendriplex 
bands. This difference was a substantial value up until 24 h when it dropped to zero. 
These results indicate a gradual time-controlled degradation of the dendrimer and 
liberation of its siRNA cargo from between 12 to 24 h.  
 
Figure 26. Hydrolysis of dendrimer Si–O bonds results in a time-dependent liberation of siRNA 
from complexation with 2G-NN16. (A) Images of siRNA migration in gels after various time periods 
of incubation with dendrimer. Lanes treated with heparin indicate total siRNA contained in dendriplex. 
(B) Graphical analysis of siRNA band intensities. 
4.4 Protection from RNase digestion 
4.4.1 siRNA/CBS dendriplex protective effect  
Agarose gel electrophoresis was used to characterize a possible protective 
effect that CBS dendrimer has on siRNA. As shown in Figure 27, naked siRNA was 
seen to be completely degraded in the presence of RNase, while siRNA retained in the 
gel wells due to its union with CBS showed very little sign of RNase degradation. 
Furthermore, the small amount of siRNA that was not bound to the dendrimer and 
was free to migrate in the gel disappears when in the presences of RNase.  
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Figure 27. Protection from degradation by RNase. siRNA complexed with 2G-NN16 is not 
degraded by RNase. 
 To further corroborate these results, similar experiments were run with the 
additional step of using heparin to liberate the dendrimer-complexed siRNA after 
incubation with RNase. The resulting siRNA gel bands represent the total quantity of 
siRNA that was not affected by RNase digestion. Figure 28 shows the siRNA gel 
bands along with a graphical representation of their relative intensities. 2G-NN16 
dendrimer protected siRNA from degradation by RNase by around 40% over non-
complexed siRNA.  
 
Figure 28. Quantification of protective effect 2G-NN16 dendrimer has over siRNA. 
4.4.2 siRNA/PEI-PEG polyplex protective effect 
 The protective nature that PEI polymer and PEI-PEG copolymers have over 
siRNA when exposed to RNase was shown by Mao, et al. (2006) [89]. The relative 
extent to which the polymers exerted a protective effect depended on the size/number 
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of PEG moieties as copolymers containing larger/fewer moieties exerted a higher 
level of protection while PEI(25k) and PEI(25k)-PEG(550)30 offered very little 
protection from RNase degradation (protective effect: PEI(25k)-PEG(20k)1 > 
PEI(25k)-PEG(5k)4 > PEI(25k)-PEG(2k)10 > PEI(25k) > PEI(25k)-PEG(550)30) (data 
not shown). 
 
4.5 Cytotoxicity 
4.5.1 Cytotoxicity of dendrimers 
The main cellular targets for HIV infection are lymphocytes. Therefore, in-
depth analysis of possible cytotoxicity on this cell type caused by treatments with 
siRNA and its proposed delivery vehicles were carried out. Dendrimers alone and 
dendriplexes were tested on lymphocytes for a toxic effect using an array of assays to 
measure cell viability, membrane rupture, metabolic activity, and cell proliferation. 
The experimental dendrimer concentrations were based on the amount necessary to 
form complexes with functional concentrations of siRNA. For instance, the top limit 
of siRNA concentration used to achieve a biological function (500 nM) requires only 
12 µg/ml 2G-NN16 to obtain a +/- charge ratio of 2. 
 
4.5.1.1 Effect on lymphocytes  
4.5.1.1.1 Lactase dehydrogenase (LDH) assays 
To test membrane rupture, LDH assay was utilized on the lymphocytic cell 
line SupT1 with 10% LDH release representing a limit above which treatments were 
considered toxic. At 3 h post-treatment, 2G-NN16 alone was determined to exert a 
toxic effect when used at concentrations above 15 µg/ml. Meanwhile, when 
complexed with siRNA (250 nM), a toxic effect was not reached until slightly more 
than 25 µg/ml 2G-NN16 (Figure 29) corresponding to a +/- charge ratio of 8.  
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Figure 29. LDH release from SupT1 cells treated with varying concentrations of dendriplex or 
dendrimer alone. (Values are relative to cells treated with Triton X-100) 
4.5.1.1.2 MTT assays 
Mitochondrial metabolism was measured by MTT assay for both SupT1 cells 
and primary PBMC treated with dendriplex. In both cell types, mitochondrial activity 
remained higher than a viability limit of 80% when subjected to dendriplex treatments 
of up to 24 µg/ml (Figure 30). 
 
Figure 30. MTT reduction by SupT1 and PBMC treated with dendriplex at varying 
concentrations. (Values relative to untreated control cells) 
4.5.1.1.3 Viability via flow cytometry  
Cell viability was measured using flow cytometry where cells were deemed 
viable if they fell within the established area of healthy cells in size/complexity dot 
plots. The gates designating viable cells were established based on the average size 
and complexity of healthy control cells. Figure 31 shows an example dot plot for 
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SupT1 cells treated with siP24-Cy3. The cells that were considered to be healthy all 
fell inside the gated region labeled “viable”. In addition to determining percentage 
viability, transfection efficiency was determined by measuring only the “viable” cell 
population for fluorescence. 
 
Figure 31. Example dot plot obtained from control cells indicating viable SupT1 cells. 
Cells treated with varying concentrations of dendrimer or dendriplex were 
analyzed by flow cytometry to detect the percentage of events that fell within the 
healthy gates on the dot plot. Again results show that dendrimer alone is slightly more 
toxic than when complexed with siRNA (Figure 32). At higher dendrimer concen-
trations (above 25 µg/ml), more cell loss is detected at 24 h than at 3 h. The results 
mirror LDH toxicity results in that at 25 µg/ml, around 10% of the cell population 
cannot be deemed viable.  
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Figure 32. Percentage viable SupT1 cells after treatment with 2G-NN16 dendrimer alone or 
complexed with siRNA after 3 and 24 h determined from flow cytometry analysis. 
4.5.1.1.4 Absolute cell counts  
The results already described provided evidence that the structural integrity 
and metabolic function of cells were not damaged from treatment with 2G-
NN16/siRNA dendriplex up to a certain concentration. However, more subtle effects 
on cells can be measured with simple cell counts and by measuring proliferation rates 
for samples undergoing treatment. Absolute cell counts were made by counting the 
cells contained in equal volumes of different samples through the use of a Neubauer 
slide and a light microscope. Results revealed that treatment with dendriplex caused a 
slight diminishing of total cell numbers with increasing dendrimer concentration 
(Figure 33).  
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Figure 33. Cell counts 96 h after SupT1 cells were treated with dendrimer alone or complexed 
with siRNA. Lipofectin was utilized as a comparative control. (Results are from one experiment 
representative of various experimental repetitions) 
4.5.1.1.5 Cell proliferation 
As another method of quantifying cell numbers, a bromodeoxyuridine (BrdU) 
proliferation kit was utilized. This test corroborated the previous results showing that 
dendriplex did not induce proliferation in SupT1 cells after either 20 or 48 h (Figure 
34). 
 
Figure 34. Proliferation in SupT1 cells treated with varying concentrations of dendriplex or 
siRNA alone (BrdU assay). 
4.5.1.2 Effect on astrocytes  
 With the cytotoxicity levels of CBS dendrimers and dendriplexes on 
lymphocytes determined, next, the astrocytic cell line U87MG and NHA primary 
human astrocytes were tested. Being one of the prime cell types of the central nervous 
system infected by HIV, astrocytes are another candidate for antiviral siRNA therapy. 
If the treatment is able to cross the blood brain barrier and reach these cells, it must be 
able to achieve a biological effect without causing cytotoxicity. Therefore, several in 
vitro assays to determine the degree of cytotoxicity of the treatment on these cells 
were carried out. 
 
4.5.1.2.1 LDH assay 
LDH release was first tested with U87MG cells for 3, 5 and 24 h incubation 
times with varying concentrations of 2G-NN16 dendrimer alone (Figure 35). Despite 
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fluctuations for points at lower concentrations, the percentage LDH release relative to 
cells treated with Triton X-100 was almost always below 10% for all time points and 
dendrimer concentrations. 
 
Figure 35. LDH release from U87MG cells 3, 5 and 24 h after being treated with 2G-NN16 
dendrimer alone. (Values are relative to cells treated with Triton X-100) 
4.5.1.2.2 MTT assays  
Mitochondrial function for U87MG cells and NHA primary cells treated with 
CBS dendrimer was measured. Results for MTT assays with U87MG cells showed 
that the dendrimer did not negatively affect the metabolic function of the cells up to 
concentrations of nearly 25 µg/ml for incubation times of 24 or 72 h (Figure 36). 
 
Figure 36. MTT reduction by U87MG after 24 or 72 h incubation with dendrimer alone at 
varying concentrations.  
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When these same cells were tested with four different siRNAs either alone or 
complexed with 2G-NN16 at a dendrimer concentration of 24 µg/ml, metabolic 
function remained stable up through 72 h (Figure 37).  
 
Figure 37. MTT reduction by U87MG cells treated with siRNA alone (250 nM) or complexed 
with dendrimer (+/- ratio, 8; [2G-NN16] = 24 µg/ml). 
Similarly, primary NHA human astrocytes retained proper mitochondrial 
function when treated with the same dendrimer concentrations after either 24 or 72 h 
(Figure 38). 
 
Figure 38. MTT assay shows the toxic effect of 2G-NN16 dendrimer alone on NHA cells after 24 
or 72 h incubations. 
4.5.1.2.3 Cell proliferation 
 Utilizing the same test that was used with lymphocytes, U87MG astrocytes 
were tested for cell proliferation by quantification of BrdU incorporation in the newly 
synthesized DNA of replicating cells. The measurements were assessed relative to 
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results for untreated cells. In spite of a slight increase in cell proliferation for 
dendrimer concentrations above 25 µg/ml, the results show that dendrimers at 
working concentrations had little effect on cell proliferation and indeed did not cause 
a reduction in cell replication (Figure 39). These data are further evidence of a lack of 
cytotoxicity by the CBS dendrimer 2G-NN16. 
 
Figure 39. Proliferation in U87MG cells 20 h after treatment with varying concentrations of 2G-
NN16 alone as measured by incorporation of BrdU in newly synthesized DNA (BrdU assay). 
4.5.1.2.4 Microarray gene profiles for dendrimer-treated U87MG  
The effect of 2G-NN16 in U87MG global gene expression profile was studied 
using Agilent 4x44K whole genome human microarrays. Analysis of microarrays 
from U87MG exposed to 23µg/ml (5µM) 2G-NN16 compared to control U87MG did 
not reveal any statistically significant gene expression variation, as the lowest 
adjusted p-value obtained by Limma-software was 0.66 (Figure 40). The lack of 
variation in the gene expression profile from control cells gave further evidence that 
2G-NN16 did not negatively effect the astrocytic cell line in any way. Furthermore, as 
no gene inducing apoptosis or cell cycle arrest was seen to be over-expressed or 
under-expressed, the likelihood of more long-term detrimental effects from the 
dendrimer treatment was minimal. 
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Figure 40. Microarray scatter plot shows no statistically significant gene expression variation. 
(p≥0.66) 
4.5.1.3 Effect on erythrocytes 
4.5.1.3.1 Hemolytic activity 
 The possible cytotoxic effects dendrimers could have on erythrocytes were 
measured by detecting erythrocyte membrane rupture and release of hemoglobin by 
colorimetric tests. As with other cytotoxicity tests, the release of hemoglobin was 
relatively low up to a dendrimer concentration well above 25 µg/ml (Figure 41). 
Also, as with other tests, siRNA/2G-NN16 dendriplexes exerted less of an effect on 
the cells than dendrimer alone.  
 
Figure 41. Graphical representation of hemoglobin released from erythrocytes 1 h after being 
treated with dendrimers or dendriplexes at varying concentrations. (Values are relative to cells 
treated with Triton X-100) 
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4.5.2 Cytotoxicity of polymers 
Experiments on the cytotoxicity of PEI-PEG copolymers on several cell types 
were also carried out. In tests similar to those carried out on dendrimers, 
mitochondrial function, membrane rupture, cellular aggregation and cellular viability 
were assayed using lymphocytes, erythrocytes and murine fibroblasts. 
 
4.5.2.1 Effect on L929 mouse fibroblasts  
4.5.2.1.1 MTT assays 
Following an incubation time of 24 h with varying concentrations of polymers, 
including PEI(25k), PEI(25k)-PEG(550)30 and other copolymers possessing 
characteristics similar to the copolymers used throughout the remainder of this study, 
the mitochondrial activity was measured revealing an approximate toxicity limit for 
each polymer tested. The polymer with the greatest toxic effect on these cells was the 
unmodified PEI(25k) (Figure 42). The unshielded charged amines of the PEI likely 
caused more damage to the cells being tested. In contrast to PEI(25k), the copolymer 
with the largest PEG moiety engraftment, PEI(25k)-PEG(30k)1, and the one with the 
largest number of PEG moieties, PEI(25k)-PEG(550)30, were around ten fold less 
toxic. The copolymer with PEG moieties of 5 kDa, PEI(25k)-PEG(5k)2, showed 
cytotoxicity at levels falling between the toxicity limits for the ungrafted and the 
highly grafted copolymers. This higher toxicity is likely caused by the fact that only 
two PEG engraftments of 5 kDa in size are not sufficient to shield all the charged 
amines of the PEI and protect the cells from the damage caused by interaction with 
the positive charges. 
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Figure 42. MTT reduction by L929 fibroblasts after treatment with polymers. The value for the 
median effective concentration required to produce an effect of 50% toxicity (EC50) was calculated 
from the regression curves applied to the toxicity results and is reported in the graph legend. 
4.5.2.2 Effect on Lymphocytes  
4.5.2.2.1 LDH assays 
4.5.2.2.1.1 LDH release by SupT1 
Next, the cytotoxicity of all the polymers was tested on lymphocytes, the main 
cell type susceptible to HIV infection. As these cells would be the primary target for 
an anti-HIV therapy involving siRNA delivered with either dendrimers or polymers, it 
was important to establish what the cytotoxicity limits were for each possible drug 
delivery candidate. It was also a way to compare different methods of improving the 
biocompatibility of the polymers via PEGylation. PEGylation can make up for the 
slightly lower efficiency at siRNA complexation it causes by reducing the overall 
toxic effects caused by the polymer. Therefore, higher concentrations of PEG-grafted 
polymers can be utilized without causing the same level of cytotoxicity. Upon 
comparing the cytotoxicity caused after 3 h incubation with polyplexes composed of 
siRNA and each of five different polymers on SupT1 cells via LDH assays, a clear 
trend appeared (Figure 43). Un-grafted PEI(25k) polymer exerted the highest 
toxicity, as was to be expected. But as the number of PEG moieties grafted to the 
polymer increased and the size of the PEG moieties decreased, the toxic effect 
subsided. PEI(25k)-PEG(20k)1 was only slightly less toxic than similar concentrations 
of un-grafted PEI(25k). However, PEI(25k)-PEG(5k)4, PEI(25k)-PEG(2k)10, and 
PEI(25k)-PEG(550)30 caused gradually decreasing cytotoxicity when polyplexes 
containing these polymers were incubated with the SupT1 cells.  
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Figure 43. LDH release from SupT1 cells 3 h after being treated with PEI-PEG/siRNA polyplexes 
as a function of PEI-PEG polymer concentration (mg/ml). N/P ratios were constant for all 
concentrations: PEI, N/P=5; all PEI-PEG copolymers, N/P=10. (Cell viability was determined by LDH 
release relative to untreated cells, and 0% viability was established by cells treated with Triton X-100) 
 Different polymers with different PEG moieties can complex siRNA with 
more or less effectivity and likewise cause higher or lower levels of cytotoxicity. 
Figure 44 shows how the cytotoxicity of the different polymers correlates to the 
quantity of siRNA in each treatment. Since all treatments for each polymer were 
mixed with siRNA at the same N/P ratio according to the optimal results in 
complexation and condensation studies, the concentration of polymer contained in 
each treatment was directly proportional to the concentration of siRNA. These results 
show that for treatments containing the maximum amount of siRNA that is likely 
necessary to achieve a biological effect (0.5 µM), the polyplex causes no cytotoxicity 
for any of the polymers. In fact, for all the polymers except for PEI(25k)-PEG(20k)1 
up to five times that concentration still did not cause cytotoxicity, and for PEI(25k)-
PEG(20k)1, two times the effective concentration could be safely administered. 
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Figure 44. LDH release from SupT1 cells 3 h after being treated with polyplex as a function of 
siRNA concentration. N/P ratios were constant for all concentrations: PEI, N/P=5; all PEI-PEG 
copolymers, N/P=10. (Values are relative to cells treated with Triton X-100) 
4.5.2.2.1.2 LDH release by PBMC 
With the extent of membrane rupture caused by the PEI-PEG polymers on 
SupT1 cells established, next, LDH assays were carried out to measure the same 
effect on primary PBMCs. A similar trend was observed with these cells (Figure 45). 
Once again, PEI(25k) and PEI(25k)-PEG(20k)1 were more toxic than the more highly 
grafted copolymers. PEI(25) was the most toxic, while PEI(25k)-PEG(550)30 was the 
least.  
 
Figure 45. LDH release from PBMC primary cells 3h after being treated with PEI-PEG/siRNA 
polyplexes as a function of PEI-PEG polymer concentration (mg/ml). N/P ratios were constant for 
all concentrations: PEI, N/P=5; all PEI-PEG copolymers, N/P=10. (Cell viability was determined by 
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LDH release relative to untreated cells, and 0% viability was established by cells treated with Triton X-
100) 
Unsurprisingly, the results showed that PBMC were not more susceptible to 
toxic effects than the established cell line, SupT1, as treatments necessary to deliver 
working concentrations of siRNA all fell below the toxicity limit of 10% (Figure 46). 
 
Figure 46. LDH release from PBMC primary cells 3 h after being treated with polyplex as a 
function of siRNA concentration. N/P ratios were constant for all concentrations: PEI, N/P=5; all 
PEI-PEG copolymers, N/P=10. (Values are relative to cells treated with Triton X-100) 
4.5.2.2.2 Viability via Flow Cytometry 
4.5.2.2.2.1 Viability of SupT1 
Utilizing the same criteria for determining the cell viability as for flow 
cytometry experiments with dendriplex, percentages of viable cells was measured 
after treatments with varying polyplex concentrations. In these experiments, the 
siRNA concentration was held constant at 500 nM while the N/P ratio was varied 
resulting in a range of polymer concentrations in the polyplex treatments. With SupT1 
cells, viability did not drop below 90% of control values after 24 h of incubation with 
the treatments for any of the polymers at all N/P ratios tested except for the highest 
N/P values each for PEI(25k) (N/P = 15) and PEI(25k)-PEG(20k)1 (N/P = 20) which 
resulted in viability of 76% and 77%, respectively (Figure 47). PEI(25k) also seemed 
to have a more rapid effect on the cells as the polymer at an N/P value of 15 resulted 
in less than 70% viability after only 3 h. 
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Figure 47. Graphs showing flow cytometry results for SupT1 cells 3 h (left) and 24 h (right) after 
treatment with polyplexes of varying concentration. Cell viability is based on viability gates in 
size/complexity dot plots (see Figure 31). Values are relative to untreated cells. [siP24-Cy3] = 500 nM; 
N/P ratios indicated in 3 h graph for all PEI-PEG copolymers in upper boxes and for PEI in lower 
boxes. 
4.5.2.2.2.2 Viability of PBMC 
As for PBMC, these cells were more susceptible to damage caused by the 
treatments with polyplexes. After only 3 h incubation, the cell viability was detected 
to drop below 90% for the same treatments that were seen to be toxic for SupT1 after 
24 h, as well as the treatment of PEI(25k)-PEG(20k)1 at an N/P ratio of 15. After 24 h 
incubation, the N/P ratio of 10 for PEI(25k)-PEG(20k)1 also resulted in a cell viability 
slightly below 90% (86%), and the highest two N/P ratios (15 and 20) for both 
PEI(25k)-PEG(2k)10 and PEI(25k)-PEG(5k)4 also caused the cell viability to drop 
below 90% (Figure 48). 
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Figure 48. Graphs showing flow cytometry results for PBMC cells 3 h (left) and 24 h (right) after 
treatment with polyplexes of varying concentration. Cell viability is based on viability gates on 
size/complexity dot plots (see Figure 31). Values are relative to untreated cells. [siP24-Cy3] = 500 nM; 
N/P ratios indicated in 3 h graph for all PEI-PEG copolymers in upper boxes and for PEI in lower 
boxes. 
4.5.2.3 Effect on erythrocytes 
4.5.2.3.1 Hemolytic activity 
As had been done with dendrimers, erythrocytes were utilized to determine 
cytotoxic effects on blood cells other than lymphocytes. The cytotoxicity was 
measured by release of hemoglobin as a result of cell membrane rupture. Similar to 
cytotoxicity results already obtained, PEI(25k) had the greatest cytotoxic effect, while 
the PEG grafted copolymers showed a negligible release of hemoglobin (Figure 49). 
 
Figure 49. Percentage of erythrocyte hemolysis after treatments with polymers alone. 
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4.5.2.3.2 Erythrocyte aggregation 
In addition to detecting erythrocyte rupture and the release of hemoglobin, these cells 
were assayed for more subtle effects, which can be seen when multiple cells aggregate 
or clump together. Erythrocyte aggregation occurs from slight morphological defects 
in the cells caused by the interaction with the molecules of a treatment and can result 
in problems in blood viscosity and microcirculation. Testing for erythrocyte 
aggregation is a good method for determining if a pharmaceutical will be toxic when 
used in vivo even if in vitro cytotoxicity results come up negative. Erythrocytes were 
treated with three of the five copolymers without siRNA and examined under a light 
microscope to detect aggregation and morphological changes in the cells (Figure 50). 
Treatment with PEI(25k) resulted in the most aggregation, while treatments with 
PEI(25k)-PEG(550)30 or PEI(25k)-PEG(20k)1 caused minimal aggregation and slight 
morphological deformity. When compared with cells treated with Lipofectamine, 
however, the copolymer treated cells appeared to be much less affected, as the 
Lipofectamine treated cells possessed a high percentage of poikilocytes with a large 
degree of deformation.  
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Figure 50. Erythrocyte aggregation when treated with polymers alone. Untreated cells and 
Lipofectamine treated cells were used as comparative controls. 
 
4.6 Transfection efficiency  
4.6.1 Dendriplex 
4.6.1.1 Uptake by lymphocytes 
4.6.1.1.1 Uptake by SupT1 
Flow cytometry was used to detect the entrance of fluorochrome-labeled 
siRNA either alone or complexed with 2G-NN16 dendrimer into viable SupT1 cells. 
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At 3 h, the highest transfection efficiency was interestingly detected for siRNA alone 
and at +/- charge ratios of 2 and 1 (86, 84 and 81%, respectively) (Figure 51A). For 
higher +/- charge ratios, not only a lower transfection efficiency was measured, but 
also a diminished quantity of viable cells were seen inevitably due to toxic effects. By 
24 h, the percentages of successfully transfected cells for all treatments with siRNA 
were all 100%, and the intensity of fluorescence emitted by the cells was substantially 
higher, as could be seen by the shift to the right of the histograms and according to x-
median values (data not shown), indicating a large quantity of siRNA in the interior of 
each cell (Figure 51B and C). Note that B is an overlay plot of the data shown in A. 
Nearly identical results were obtained when PBMC were tested instead of SupT1 
(data not shown). 
 
Figure 51. Histograms show successful transfection by dendriplex. Transfection efficiency is shown 
by flow cytometry of SupT1 cells 3 h after treatment with siRNA or dendriplexes (A) (+/- charge ratio 
indicated in parentheses) and overlay plots for all samples at both 3 (B) and 24 h (C). 500 nM siRNA 
for all points. 
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4.6.1.1.2 Uptake by HIV-infected PBMC  
Next, toxicity and transfection efficiency were tested for siRNA and 
dendriplex treatments on HIV-infected PBMC. At 3 h, unlike with the SupT1 cells, 
naked siRNA was unable to enter the PBMC, but when complexed with 2G-NN16 
successful transfection was obtained with a maximum at +/- ratio of 2 (41%) (Figure 
52A). Despite this difference, toxicity profiles for these cells mimicked the results for 
SupT1. By 24 h, much higher transfection efficiency was seen for naked siRNA as 
well as +/- ratios of 1 and 2. Lipofectin® also exhibited higher transfection efficiency 
at 24 h compared to 3 h, however not to the extent of 2G-NN16 (Figure 52B). The 
percentage of viable cells was lower as a whole for these cells, as a result in part of 
the HIV infection, but no substantial difference was detected between control cells 
and those treated with dendriplex. Meanwhile, Lipofectin® exhibited a larger decrease 
in cell viability compared to the control cells. 
 
Figure 52. Transfection and toxicity profiles of dendriplexes on HIV-infected PBMC. Dendriplex 
at varying +/− charge ratios after 3 h incubation (A) and 24 h incubation (B). Toxicity was measured 
by LDH enzyme release (A), while transfection and cell viability was measured by flow cytometry (B). 
Lipofectin® was used as a comparative control for both toxicity and transfection. 
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4.6.1.2 Uptake by astrocytes  
U87MG cells showed positive results for transfection with dendriplexes made 
of 2G-NN16 and Cy3-labeled siRNA. Figure 53 indicates the percentage of viable 
cells with detectable fluorescence as measured via flow cytometry after 3 h for cells 
treated with 250 nM sP24-Cy3 alone or in dendriplex at +/- charge ratios of 2, 4, or 8. 
The highest transfection rate after this short time period corresponds with the highest 
+/- charge ratio for the dendriplex (i.e. the highest concentration of 2G-NN16). Unlike 
for lymphocytes, neither a lower +/- charge ratio such as 2 nor siRNA alone showed 
high positive transfection of the astrocytoma cells after only 3 h. With lymphocytes, 
the exact opposite trend had been observed. 
 
Figure 53. Dot plots and histograms indicate percentage uptake by viable U87MG cells 3 h after 
treatment with dendriplex of varying +/- charge ratios. ([siRNA] = 250 nM; +/- charge ratio 
indicated in parentheses) 
Regardless of these differences, after 18 h, all treatment samples (siRNA alone 
or in dendriplex at +/- charge ratios of 2, 4 or 8) showed very high levels of 
transfection. Figure 54 shows that 90% of all viable U87MG cells showed siP24-Cy3 
uptake regardless of the amount of 2G-NN16. 
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Figure 54. Histograms show successful transfection of U87MG cells 18 h after treatment with 
siRNA alone or dendriplexes at varying +/- charge ratios. ([siRNA] = 250 nM; +/- charge ratio 
indicated in parentheses) 
In addition to achieving uptake in a high percentage of astrocytoma cells, the 
quantity of siRNA that was taken up by the cells was measured by quantifying the 
average intensity of the fluorescence for each cell showing sufficient fluorescence to 
be considered positive for siRNA uptake. This value, referred to as the x-median of 
fluorescence, appeared to increase as the +/- ratio of dendrimer to siRNA increased 
for dendriplex-treated cells when measured after 3 h (Figure 55). The highest +/- ratio 
tested was 8 and showed an equally high level of fluorescence intensity as cells 
treated with Lipofectin®. This indicates that dendriplexes were successful at 
transfecting siRNA into astrocytoma cells, and that a high amount of siRNA reached 
the interior of the cell when complexed with 2G-NN16. The importance of this is 
highlighted by the fact that the biological function of siRNA takes place in the 
cytoplasm, where the two strands of the siRNA are separated and incorporated into 
the RISC complex.  
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Figure 55. X-median of fluorescence intensity in U87 cells 3 h after treatment with dendriplexes. 
Lipofectin® was used as a comparative control. (Values represent the average intensity of fluorescence 
among all viable cells that show sufficient fluorescence intensity to be considered positive for siRNA 
uptake (≥ 100); [siRNA] = 250 nM) 
4.6.2 Polyplex 
4.6.2.1 Uptake by lymphocytes 
4.6.2.1.1 Uptake by SupT1 and PBMC 
To initially test transfection efficiency of the various PEGylated polymers, 
polyplexes made of polymers and Cy3-labeled siRNA were administered to either 
SupT1 cells or PBMC, and samples were collected and analyzed by flow cytometry 
after 3 or 24 hours to detect cells emitting fluorescence indicating a positive uptake of 
siRNA. All treatments were made with a constant concentration of siP24-Cy3 (500 
nM), but the polymer concentrations varied as a scale of N/P ratios was tested. All the 
polymers were tested at N/P ratios of 5, 7.5, 10, 15 and 20 except PEI(25k) which was 
tested at N/P ratios of 3, 5, 7.5, 10 and 15 because of its better efficiency at 
complexing siRNA and since it had exhibited higher cytotoxicity in previous 
experiments. Cells were washed with glycine acid to remove any siRNA bound to the 
exterior of the cell membrane prior to being analyzed with the flow cytometer. 
 Figure 56A and B show the flow cytometry results for polyplex-treated 
SupT1 cells and PBMC, respectively. For all the polymers in both cell lines and 
following both short and long incubation times, the transfection efficiency increased 
with increasing N/P ratios (except for PEI-PEG(5k)4 in SupT1 at 3 h which did not 
transfect the cells at any N/P ratio). This is possibly because a higher ratio of polymer 
to siRNA resulted in a more stable polyplex. Another possibility was that the 
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polyplexes of higher N/P ratios were more easily endocytosed by the cells because of 
the greater net positive charge. A third possibility is that the higher rate of uptake was 
a result of more cellular damage caused by the higher polymer concentrations. In 
general, there was a direct correlation between transfection efficiency and decreased 
cellular viability.  
 
Figure 56. Graphs showing flow cytometry results for uptake of siP24-Cy3 by SupT1 cells (A) 
and PBMC (B) for 3 h (left) and 24 h (right) after treatment with polyplexes of varying 
concentration. Values are relative to untreated cells. [siP24-Cy3] = 500 nM; N/P ratios indicated in 
each 3 h graph for PEI in upper boxes and for all PEI-PEG copolymers in lower boxes. 
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 PEI(25k) generally showed higher uptake than the rest of the polymers at 3 
hours, but by 24 hours, it was no more effective than the others. Furthermore, its 
effect on cellular viability reached a detrimental level at concentrations lower than 
those for the other polymers (Figure 47). This is inevitably due to its higher charge 
density and lack of PEG molecules to damper its effect. The only other polymer that 
caused a significant effect on cellular viability was PEI-PEG(20k)1, as the other three 
polymers did not exert much of a negative effect on the cells even at fairly high 
polymer concentrations (Figure 47). 
 
4.7 Confocal and immunofluorescence microscopy 
4.7.1 Lymphocytes 
4.7.1.1 Dendriplex 
To assure that flow cytometry results indicated a successful transfection into 
the cytoplasm of the cell as well as to further investigate the rare occurrence of 
successful uptake of naked siRNA, lymphocytes that had been treated with 
fluorochrome-labeled siRNA either alone or in dendriplex at +/- ratio of 1 or 2 were 
viewed with a scanning confocal microscope (Figure 57). The figure images are 
labeled with the percentages of cells with successful uptake of siRNA. For all 
treatments, the siRNA was clearly seen in the interior of a majority of the cells with 
the highest percentage of uptake for a +/- ratio of 1. The cells were clearly alive and 
viable as is seen in videos showing healthy, mobile cells with siRNA clearly located 
in the interior of the cells*. 
                                                
* Videos can be seen in the electronic version of this work. 
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Figure 57. Confocal microscopy overlay images show complete internalization of siRNA into T 
cells. SupT1 cells after 20 h incubation with mock treatment (A) or with siP24-Cy3 (red) alone (B) or 
complexed with 2G-NN16 at a +/- charge ratio of 1 (C) or 2 (D). Cell membranes are labeled with 
αCD45-FITC antibodies (green). Percentages of cells positive for siRNA uptake are indicated ± SD. 
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4.7.1.2 Polyplex 
The scanning confocal microscope was also used to image SupT1 cells treated with 
polyplexes composed of 1000 nM siP24-Cy3 and each of the five PEI-PEG copolymers 
after 24 h incubation. In order from the left, Figure 58 showed light microscopy images, 
images of FITC-antibody-labeled cell membranes (green), overlay images of cell 
membranes with siP24-Cy3 (red), and overlay images of cell membranes, siP24-Cy3, and 
DAPI-labeled cell nuclei (blue). It was possible to examine both the extent of siRNA 
uptake and the cell morphology from the images. In particular, the status of the cell nuclei 
revealed the effects that the treatments had on the cells. In line with the flow cytometry 
results, there was a high level of siRNA uptake from all treatments.  
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Figure 58. Confocal images of SupT1 cells 24 h after being treated with polyplexes containing siP24-
Cy3 (1000 nM). N/P ratios were 5 for PEI(25K) and 10 for all others. 
Results 
 
 
 
101 
 
 
 
Figure 59 showed a quantitative analysis of the amount of siRNA uptake and the 
estimated cell viability for the four PEG-engrafted copolymers based on the viewing of the 
photographs by independent observers. From the images, negative effects on the cells by 
PEI(25k) and PEI(25k)-PEG(20k)1 were easily observed. The percentages of cells that 
could be considered viable for these two treatments were quite low. In the case of 
PEI(25k)-PEG(20k)1, this was inevitably the result of using twice the usual polymer 
concentration (0.033 mg/ml) in order to delivery 1000 nM siRNA (0.033 mg/ml PEI(25k)-
PEG(20k)1 had shown toxicity; see Figure 47 and Figure 48). However, the other three 
copolymers showed positive results for cell viability and siRNA uptake. Specifically, the 
cells treated with these polyplexes showed siRNA uptake of greater than 70%. PEI(25k)-
PEG(550)30 and PEI(25k)-PEG(5k)4 had the highest uptake (~85%) followed closely by 
PEI(25k)-PEG(2k)10 and PEI(25k)-PEG(20k)1. These results reflected precisely the same 
results that were obtained by flow cytometry (Figure 56A, 24 h). 
 
Figure 59. Visual analyses of confocal images in Figure 58 revealed viability and transfection data for 
the different polyplex treatments. [siRNA] = 1000 nM; [PEI-PEG] = 0.033 mg/ml. 
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4.7.2 Astrocytes 
4.7.2.1 Dendriplex 
Immunofluorescence microscopy was used to analyze uptake of Cy3-labeled 
siRNA by U87MG cells. Microscopy images corroborated flow cytometry results 
indicating no uptake for siRNA (250 nM) alone and increased uptake with higher +/- 
ratios when siRNA is complexed with 2G-NN16 dendrimer. Because of the adherent 
nature of this astrocytic cell line resulting in planar dendritic cells attached to the 
surface of the microscope slide, obtaining a quality confocal sectional cut showing the 
interior of the cells is difficult. Thus immunofluorescence microscopy was utilized 
instead. By labeling the nucleus with DAPI and attempting to bring the nucleus into 
focus, it could be estimated whether or not the fluorochrome-labeled siRNA had 
gained entrance into the interior of the cells. The images obtained appear to show the 
interior of the cells and show the aggregation of Cy3 fluorescence in small clusters as 
well as regions where the fluorescence is more dispersed (Figure 60). This is 
evidence that the dendriplexes were endocytosed and are located inside internal 
vesicles as well as having dispersed throughout the cytoplasm.  
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Figure 60. Immunofluorescence microscope images of U87MG cells 24 h after being treated with 
siP24-Cy3 alone (250 nM) or in dendriplex. siP24-Cy3 appears red and DAPI-labeled nuclei appear 
blue. 
 
4.8 Dendriplexes pass through biological membranes  
4.8.1 Monolayer of polarized epithelial cells  
To evaluate the ability of dendriplexes to cross biological barriers, we used a 
human epithelial cell barrier (tight monolayer of polarized HEC-1A epithelial cells) in a 
transwell system. This method is inadequate at fully representing a model for the BBB, 
but most BBB models typically are not able to generate a tightly formed monolayer of 
cells without fenestrations. Therefore, in order to prevent passive diffusion of the 
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dendriplexes through discontinuities in the monolayer, polarized epithelial cells were 
used to form a tightly bound monolayer [117]. FITC-labeled-siRNA alone or complexed 
with NN16 dendrimers were added to the apical zone with previously activated PBMCs 
in the basolateral zone of the chamber of the transwell system. PBMCs were utilized to 
more easily determine uptake of the siRNA and, hence, the transcytosis of the 
dendriplex or siRNA alone through the biological barrier since the kinetics of PBMC 
transfection had been more thoroughly studied. Subsequently, the PBMCs were 
collected after 5 or 72 h and analyzed by flow cytometry for siRNA uptake. We did not 
find any fluorescence in cells after the short incubation times (5 h) (Figure 61A), 
whereas we did find an increase in the transfection capacity of cells treated with siRNA 
alone by 52% and in cells treated with dendriplexes by 83% after 72 hours (Figure 
61B). The monolayer was viewed with a light microscope to assess its integrity and lack 
of apparent fenestrations prior to undergoing experiments (Figure 61C). However, even 
more convincing evidence that the monolayer was completely intact was the fact that 
there was no siRNA uptake after the shorter incubation times (5 h). Had there been holes 
in the monolayer allowing the dendriplex to freely diffuse across the barrier, the results 
would have more resembled the prior flow cytometry results of siRNA uptake for 
PBMCs in which transfection was detected after only 3 h (Figure 52). In addition, 
treatments with dendriplexes were not toxic at the dose used. 
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Figure 61. Transcytosis through an epithelial cell barrier. In a transwell chamber, FITC-labeled-
siP24 alone or FITC-labeled-siP24/2G-NN16 was added to the apical face of a tight monolayer of 
polarized epithelial cells, HEC-1A. Five h (A) or 72 h (C) later, activated PBMCs were collected from 
the basolateral zone and the transfection was analyzed by flow cytometry. Prior to treatment the 
integrity of the epithelial monolayer was imaged by light microscopy (C) stained with AgNO3 (above) 
and without staining (below). 
4.8.2 Monolayer of a bovine brain microvascular endothelial cells 
 An even better system for assessing the potential capability of crossing the 
BBB is accomplished through the use of bovine brain microvascular endothelial cells 
in a transwell chamber. The formation of a tight monolayer with 100% confluence 
was determined by measuring the transepithelial electric resistance and was 
monitored with a light microscope. An image of the monolayer can be seen in Figure 
62A. As before, FITC-labeled siP24 either alone or complexed to 2G-NN16 was 
added to the apical zone. For these experiments, either PBMC or U87MG were 
seeded in the basolateral zone and tested for siRNA uptake by flow cytometry either 5 
or 72 h after the treatment. As with the epithelial cell barrier system, uptake of siRNA 
by the cells in the basolateral zone indicated successful transcytosis of the cell 
monolayer barrier and subsequent transfection of the target cells. For PBMC, there 
was no siRNA uptake after only 5 h (Figure 62B), but positive transcytosis and 
transfection for both siRNA alone and dendriplex after 72 h (Figure 62C). With 
U87MG astrocytes in the basolateral zone, the experiment modelled the in vivo 
system in both the cells that form the blood brain barrier and the target cells. These 
experiments revealed no uptake after 5 h (Figure 62D), but a three-fold higher 
transfection than with the PBMC after 72 h (Figure 62E). Both siRNA alone and 
bound to dendrimers showed positive transcytosis and transfection by the target cells. 
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Figure 62. Transcytosis of a BBB model. Bovine brain microvascular endothelial cells were grown 
into a tight monolayer (A) in a transwell chamber. FITC-labeled siRNA (250 nM) alone or in 
dendriplex with 2G-NN16 (+/- ratio of 8) were added to the apical face of the transwell with either 
activated PBMC (B & C) or U87MG cells (D & E) in the basolateral zone. After 5 h (B & D) or 72 h 
(C & E), the cells from the basolateral zone were collected and analyzed by flow cytometry for siRNA 
uptake. Untreated cells were used as a mock control. 
4.9 Biological activity of siRNA 
4.9.1 Silencing effect by siRNA via electroporation  
Prior to attempting HIV inhibition experiments using siRNA complexed with 
dendrimers or polymers, the efficacy of the siRNA at inhibiting HIV needed to be 
determined. To carry this out, HIV-infected PBMC were subjected to treatment with 
siRNA via electroporation. Flow cytometry data showed that electroporation resulted 
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in successful transfection of Cy3-labeled siRNA (Figure 63). Cells washed with 
trypsin to remove molecules on the membrane showed similar levels of Cy3 
fluorescence indicating uptake into the cell interior.  
 
Figure 63. Flow cytometry indicates successful entrance of Cy3-labeled siRNA in HIV-infected 
PBMC 24h after electroporation 
As a control for siRNA entrance and function, we performed parallel 
experiments with uninfected SupT1 cells that were electroporated with siRNA 
targeted to the housekeeping gene GAPDH. The siRNA was seen to be functional as 
cells electroporated with GAPDH siRNA (siGAPDH) exhibited up to 80% silencing. 
The GAPDH knockdown was seen to be sequence-specific and dependent on siRNA 
concentration. This was determined as points treated with less than 250 nM siGAPDH 
never achieved greater than 50% knockdown while 250 and 500 nM siGAPDH 
achieved 70% and 89% knockdown, respectively, while a negative control siRNA of 
random sequence (siRandom) had either no effect or a slight effect on GAPDH 
expression (Figure 64A). Additionally, the silencing affect was seen to last up to 6 
days after only one treatment with siRNA (Figure 64B). Next, it was determined if 
this same effect could be achieved in HIV-infected PBMC via electroporation. 
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Results showed from 50% to 80% inhibition for 500 nM of a siRNA targeted to the 
HIV p24 gene (siP24) and up to 85% inhibition when targeted to the HIV gag gene 
(siGAG1) compared to mock treated cells (Figure 64C). Furthermore, there was a 
difference of at least 40% between cells treated with siGAG1 and those treated with 
siRandom for all time points. This indicates a sequence-specific inhibition of HIV for 
siRNA at this concentration. At 3 times the siRNA concentration, there was no 
improvement in viral inhibition (data not shown). Because of these results, siRNA 
concentrations were limited to between 250 nM and 500 nM for all further gene-
silencing experiments. 
 
Figure 64. siRNA transfected by electroporation. SupT1 cells showed a downregulation of GAPDH 
that was sequence-specific, affected by siRNA concentration (A), and lasted at least 6 days (B). siRNA 
targeted to HIV also showed inhibition of HIV replication when delivered by electroporation (C). 
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4.9.2 Silencing by dendriplex-delivered siRNA 
4.9.2.1 Lymphocytes  
With the efficacy of siRNA at GAPDH knockdown and inhibition of HIV 
demonstrated via electroporation, GAPDH silencing and HIV inhibition experiments 
were next carried out with dendriplexes of 2G-NN16 and siRNA. Naked siRNA was 
also tested for biological effect, and Lipofectin® was used as a comparative control. 
Expression of GAPDH in normal SupT1 cells was shown to be reduced in a sequence 
specific way when the cells were treated with naked, Lipofectin®-delivered, and 2G-
NN16-delivered siRNA (45, 46, and 47%, respectively) (Figure 65A-C).  
 
Figure 65. GAPDH expression in SupT1 cells 48 h after being treated with siRNA alone or 
complexed with Lipofectin or 2G-NN16. [siRNA] = 500 nM; +/- ratio for 2G-NN16 was 2. 
siRNA was also able to inhibit HIV when bound to 2G-NN16. Inhibition was 
achieved by both siRNA targeted to the HIV nef gene (siNEF) and a cocktail mixture 
of the three siRNAs siP24, siGAG1 and siNEF (siCOCKTAIL) (15 and 22%, 
respectively) compared to control cells (Figure 66).  
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Figure 66. Ag p24 quantity for HIV-infected SupT1 cells 24 h after being treated with 
dendriplexes of 2G-NN16 and different siRNA. [siRNA] = 500 nM; +/- ratio = 2. 
To further investigate the HIV inhibitory effect, dendriplexes at different +/- 
charge ratios along with naked siRNA were tested on HIV-infected PBMC. At 24 h, 
an inhibition of 25% is seen for siNEF and nearly 40% for siCOCKTAIL when bound 
to 2G-NN16 at a +/- charge ratio of 2 compared to control cells (Figure 67). The 
inhibition obtained with a +/- ratio of 2 is better than for a +/- ratio of 1 or naked 
siRNA. Moreover, LDH assays for these experiments show that the treatments cause 
minimal toxicity. 
 
Figure 67. Graph showing Ag p24 quantities indicates HIV replication for HIV infected PBMC 
after 24 h incubation with siRNA alone or dendriplexes at +/- charge ratio of 1 or 2. White bars 
indicate toxicity as measured by LDH release 3 h after treatment (relative to cells treated with Triton 
X-100). 
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4.9.2.2 Astrocytes  
Next, U87MG astrocytes were tested for an siRNA silencing effect. Initial 
GAPDH knockdown experiments with these cells showed slight gene silencing for 
siRNA treatment alone or in dendriplex to the amount of 12% and 37%, respectively, 
compared to mock-treated control cells (Figure 68). The silencing was sequence-
specific, because treatments with either siRandom alone or complexed with 2G-NN16 
did not result in a decrease in GAPDH expression. In addition, dendrimer alone did 
not negatively affect GAPDH expression, which indicated that cytotoxicity was not 
an issue.  
 
Figure 68. Initial GAPDH silencing experiment in U87MG cells for siRNA treatment alone or 
with 2G-NN16 (+/- ratio of 8). 
When experiments on HIV inhibition were performed with these cells, 
dendriplexes containing anti-HIV siRNA had much better efficacy at reducing the 
viral replication (Figure 69). After infecting the cells with the T-tropic HIV strain 
NL4-3, treatments with siRNA targeted to the p24 gene or the nef gene were 
administered either alone or in dendriplex. Seventy-two h later, supernatants from the 
cell plates were collected and viral RNA was quantified by qPCR. Results from the 
qPCR showed that the dendriplexes achieved the greatest level of viral inhibition. At 
an siRNA concentration of 100 nM, siNEF and siP24 reduced the viral replication by 
50% and 55%, respectively, and when the concentration of siP24 was increased to 
250 nM, the inhibitory effect improved to over 80% inhibition (Figure 69A). Similar 
results were obtained when the cells were infected with the M-tropic HIV strain Ba-L. 
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However, the maximum level of HIV inhibition with this viral strain was achieved 
with treatments of dendriplex containing 250 nM of siP24 in which the viral 
replication was reduced by 40% (Figure 69B). 
 
Figure 69. Graphs indicate a reduction in HIV replication in U87-MG cells 72 h after treatment 
with siNEF or siP24 alone or delivered by 2G-NN16. The cells were infected with the X4-HIV 
strain, NL4-3 (A), or the R5-HIV strain, Ba-L (B). Values represent Ag p24 concentration as deter-
mined by ELISA relative to untreated cells; siRandom was used as a control. 
 
4.9.3 Silencing by polyplex-delivered siRNA 
4.9.3.1 Lymphocytes 
4.9.3.1.1 GAPDH knockdown from one-time treatment 
Initial experiments on the biological effect of siRNA delivered by PEI-PEG 
polymers were attempts at GAPDH silencing following a one-time treatment and 
then, long-term GAPDH silencing through repetitive treatments. After the one time 
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treatment or polyplexes, GAPDH expression was reduced in a sequence-specific 
manner when the cells were collected 72 h after treatment for polyplexes made up of 
PEI(25k)-PEG(2k)10, PEI(25k)-PEG(20k)1, and PEI(25k)-PEG(550)30 (Figure 70B). 
When the cells were collected one day earlier (48 h after treatment), only PEI(25k)-
PEG(2k)10 showed any amount of sequence-specific GAPDH silencing (Figure 70A).  
 
Figure 70. Graphs showing relative expression of GAPDH in SupT1 cells treated with siRNA 
alone or delivered by PEI-PEG polymers after incubations of 48 h (A) and 72 h (B). [siRNA] = 
500 nM; N/P ratio 5 for PEI, 10 for all others. 
4.9.3.1.2 GAPDH knockdown over an extended time period with repetitive doses 
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GAPDH silencing experiments were extended from 3 up to 22 days. In order 
for the cells to be maintained for this longer period, the cells were diluted by 
collecting samples and replacing the lost volume with fresh medium. This allowed 
measurements of GAPDH expression to be made and treatments of PEI-PEG/siRNA 
polyplex to be repeated every 2 or 3 days. A total of 9 treatment doses and 9 
measurements were made over the course of 22 days. After taking into consideration 
all the results obtained thus far, including stability, cytotoxicity, transfection and 
biological effect, it was decided to continue experimentation with a focus on only two 
of the five polymers, PEI(25k)-PEG(2k)10 and PEI(25k)-PEG(20k)1. The results 
showed that siRNA targeted to the GAPDH gene had a greater effect on silencing 
GAPDH expression as the experiment went along when delivered by PEI(25k)-
PEG(20k)1 (Figure 71). Treatments with this polyplex reduced gene expression by 
78% and 77% on days 13 and 20, respectively, while siRandom delivered by the same 
polymer consistently resulted in GAPDH expression either equal to or greater than the 
GAPDH expression for mock treated cells. PEI(25k)-PEG(2k)10-delivered siGAPDH 
did not produce such positive results as it caused a reduction in GAPDH expression 
compared to siRandom -treated cells in only four out of nine time points. 
 
Figure 71. Graph showing relative GAPDH expression for SupT1 cells undergoing repeated 
treatments with PEI-PEG/siRNA polyplexes. [siRNA] = 500 nM; N/P ratio = 10. 
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4.9.3.1.3 HIV inhibition 
4.9.3.1.3.1 Treatment with polyplexes prior to infection with HIV 
The final experiments carried out with siRNA and PEI-PEG polymers were 
HIV inhibition experiments. First, attempts were made to inhibit HIV replication by 
submitting SupT1 cells to one-time treatments of polyplexes 24 h prior to infecting 
them with HIV. If the siRNA could transfect the cells and become functional at 
targeting the HIV RNA for degradation prior to the introduction of the viral genome, 
it could possibly prevent infection of the cell by stopping the viral cycle before 
retrotranscription took place by degrading the first template viral RNA introduced 
into the cell interior. Such a mechanism could offer the possibility of a prophylactic 
therapy for the prevention of HIV infection. The results, however, showed a very 
slight reduction in the production of p24 for cells treated with siNEF or siCOCKTAIL 
complexed to PEI(25k)-PEG(2k)10 or PEI(25k)-PEG(20k)1 compared to cells treated 
with siRandom (Figure 72). 
 
Figure 72. Relative Ag p24 for HIV infected SupT1 cells that had been treated with polyplexes 
one time 24 h prior to being infected with HIV. Ag p24 concentration was quantified by ELISA 72 h 
after infection with HIV. 
 
4.9.3.1.3.2 Repetitive treatments with polyplexes over two weeks 
Despite the less than positive results obtained from the pre-infection treatment 
experiments, further experiments on HIV inhibition were carried out. Utilizing 
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experimental protocols similar to those used for the experiments of long-term 
GAPDH silencing via repetitive treatments, HIV-infected SupT1 or PBMC were 
maintained in passage while undergoing repeated treatments to examine the more 
long-term effects that polyplexes had on the viral replication. Several days after 
SupT1 cells were infected with HIV and submitted to an initial treatment with 
polyplexes, samples were collected, the lost volume was replaced with fresh medium, 
and an additional treatment was added to each point. This procedure was repeated 
every two or three days up to 15 days. Figure 73 shows the p24 quantification results 
for six time points from day 2 to day 15 for cells infected with 100 pg HIV per 
million cells. The greatest amount of HIV inhibition was achieved by siNEF delivered 
by PEI(25k)-PEG(20k)1 which reduced the amount of HIV production by greater than 
104 fold compared to mock-treated cells and around 100 fold compared to siRandom-
treated cells. The HIV inhibition was not detected until day 7, and a difference 
between siNEF and siRandom was not seen until day 9. However, by day 15 of the 
experiment the siNEF polyplex-treated cells maintained a viral production below 100 
pg of p24 protein. The level of HIV inhibition was equivalent to the inhibitory effect 
caused by treatments of 0.5 µM AZT. 
 
Figure 73. HIV replication is inhibited over an extended time period in HIV infected SupT1 cells 
undergoing repetitive treatments with polyplexes containing anti-HIV siRNA and PEI-PEG(2k)10 
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or PEI-PEG(20k)1. Cells were infected with HIV NL4-3 at a concentration of 100 pg/106 cells; y-axis 
is logarithmic Ag p24 concentration; [siRNA] = 500 nM; N/P ratio = 10; [AZT] = 500 nM. 
When SupT1 cells were infected with ten times as much HIV (1000 pg 
HIV/106 cells), repetitive treatments still had an inhibitory effect on HIV replication. 
As before, siNEF delivered by PEI(25k)-PEG(20k)1 resulted in the greatest amount of 
HIV inhibition and, once again, mirrored the effects of AZT treatments (Figure 74). 
With the higher multiplicity of infection, mock-treated cells experienced an explosion 
in HIV replication by day 7 when p24 levels peaked and dropped off because of a 
high amount of cell death due to the high viral titer. This peak did not occur for the 
mock-treated cells infected with the lower MOI until day 12. This higher MOI was 
also responsible for the fact that the siNEF-polyplex did not maintain the viral 
replication from increasing like it had when infected with the lower MOI. Regardless, 
the difference between siNEF-polyplex treated cells and the rest of the points in the 
experiment was consistently around 100 fold. 
 
Figure 74. Equivalent results for HIV inhibition by repetitive doses of polyplexes over an 
extended time period in SupT1 cells infected with HIV NL4-3 at a concentration of 1000 pg/106 
cells. y-axis is logarithmic Ag p24 concentration; [siRNA] = 500 nM; N/P ratio = 10; [AZT] = 500 nM. 
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The goal of bringing gene therapy techniques such as RNAi to the fight 
against HIV infection holds a great deal of promise. The main hurdle to overcome in 
utilizing these powerful tools appears to be delivery and transfection of the infected 
cells. The development of a system that could address these issues could immensely 
expand the therapeutic possibilities of RNAi.  
This work presents research on two types of drug delivery vehicles and their 
capability to transport and deliver siRNA to two different cell types.  In the first 
instance, amine-terminated carbosilane dendrimers are a monodisperse, low 
molecular weight dendrimer. Second, a group of PEG-engrafted PEI copolymers 
possess a high charge density coupled with exterior protective PEG moieties to 
improve their biocompatibility.  The experimental research that was carried out can be 
divided into three sections.  First, analysis on the stability and characterization of the 
interaction between each delivery vehicle and siRNA was performed.  Second, the 
effects these molecules (either alone or complexed with siRNA) had on cells when 
treated in vitro were carefully examined.  The effects of the treatment on the cells that 
were measured included unwanted effects such as cytotoxicity, and desirable effects 
like successful transfection.  Also, the ability of these macromolecules to transverse 
biological barriers in order to reach the target cells was considered among the effects 
resulting from the interaction between the complexes and cells.  Finally, the primary 
objective of this research, achieving a biological effect from the delivery of siRNA to 
the cells and, in particular, achieving gene silencing, was thoroughly assayed at the 
end of this work. 
The structural differences between the two vehicles provide evidence for the 
advantages and disadvantages that each vehicle offers.  CBS dendrimers are a smaller 
molecule with a more defined structure possessing internal Si–O bonds that allow for 
time-controlled liberation of the exterior branches.  On the other hand, PEI-PEG 
polymers have a higher density of positively charged amines (PEI = 43 g/charge; 2G-
NN16 = 287 g/charge), which allows for both a higher N/P ratio and a lower polymer 
concentration to achieve delivery of the same amount of siRNA.  Also, the attachment 
of PEG moieties on the periphery functions to shield the high charge density of the 
PEI core and greatly improves the biocompatibility of the molecules.  This is an 
improvement over the dendrimer structure, which has its positive charges exposed on 
the surface of the molecule.  Finally, the larger molecular weight of the polymers 
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allows for complexation with a larger amount of siRNA.  The molar ratio of siRNA to 
PEI is 13.8 mol siRNA for every mol PEI, compared to 0.38 mol siRNA to every mol 
2G-NN16. With the experimental +/- charge ratios utilized, the polymer is added at a 
ratio of ten times the amount of siRNA compared to the ratio of only two for 
dendrimer.  Even so, the resulting molar ratios are 1.38 mol siRNA per mol PEI and 
0.19 mol siRNA per mol 2G-NN16.  Clearly, the polymer can achieve the same 
delivery at a substantially lower concentration than the dendrimer. 
The first results reported here dealt with the stability and characterization of 
the complex formed between the vehicles and siRNA.  The first conclusion to be 
made was that gel electrophoresis is adequate in visualizing the formation of a stable 
complex.  The siRNA complexation and condensation gels showed that PEI-PEG 
copolymers require higher N/P ratios to fully complex siRNA compared to PEI and 
2G-NN16 (Figures 20 and 23).  As described before, the presence of the PEG 
moieties shield the charged amines of the PEI core thus minimizing the exposure of 
the positive charges to components of the cell where it would have toxic effects, but 
also partially impedes the ability for the positive charges to fully and efficiently bind 
siRNA.  Therefore, a higher concentration of PEG-engrafted polymer is needed to 
fully complex the siRNA.  2G-NN16 has no such protective shield, so its positive 
charges are fully exposed and able to bind siRNA more efficiently.  The fact that 2G-
NN16 possesses two charged amines on each branch with one inside of the other is 
likely the reason that the +/- charge ratio to adequately complex siRNA is two, as 
only one of the amine pairs per branch on average can capably bind the siRNA. 
The strength of union assay simply showed that the electrostatic union 
between the vehicle and siRNA was not an entirely static interaction (Figure 21). 2G-
NN16 binds siRNA less strongly than 2G-NN8 by a slight amount. This could 
indicate a greater tendency to release the siRNA after cell transfection has occurred. It 
could also, however, indicate less protection en route to the target cells.  The only 
accurate way to answer this question would be further investigation, including in vivo 
trials. The PEI-PEG copolymers 2k, 5k, and 20k* showed similar results to the 
dendrimers in heparin competition assays in that partial release was seen at 0.21 
                                                
* Throughout the discussion, the PEI-PEG polymers may be referred to simply by the mass of their 
PEG attachments or without including the PEI in the name.  Thus, “2k” and PEG(2k)10 refer to 
PEI(25k)-PEG(2k)10 unless otherwise specified. 
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IU/µg with full release at 0.31 IU/µg [89]. It was also shown that the presence of PEG 
moieties prevented the polymer from binding the siRNA much more strongly, which 
is further evidence of their effect at shielding the high charge density of the PEI core. 
Dynamic light scattering assays on dendriplexes showed that both size and 
zeta potential depended on +/- charge ratio (Figure 22) and [121].  Utilizing the zeta 
potential assay, it was determined that the naturally occurring +/- charge ratio of 
dendriplexes between 2G-NN16 and siRNA was about 3:1.  At smaller +/- ratios, 
there was not sufficient protection by the dendrimer and the zeta potential reflected 
the high density of negative charges of the siRNA in the complex. The assays also 
showed that beginning at 3, as the +/- charge ratio increased, there was a greater 
likelihood of aggregation.  Particle size at +/- ratio of 3 was greater than 300 nm, 
whereas at +/- ratio of 2 it was smaller at just over 200 nm. Meanwhile, polyplexes 
tested at an N/P ratio of ten had a smaller particle size and a positive zeta potential 
(Figure 24). The difference between this and the zeta potential of dendriplexes is 
clearly because of the difference in charge ratios utilized. Among the different 
copolymers, it appears that the larger PEG chains condensed the siRNA better and 
resulted in particle sizes of around 150 nm.  It is likely that the PEG moieties also 
helped significantly in preventing aggregation, supported by the fact that PEI(25k) 
showed a gradual increase in particle size during the 20 min duration of the 
experiment (data not shown), probably because of aggregation [89]. The PEG(550)-
engrafted polymer seemed to not be sufficient to condense the siRNA fully as particle 
size was over 300 nm. 
The most intriguing attribute of the CBS dendrimer was its ability to enact a 
time-controlled release. The difficulty in synthesizing gradually degrading dendrimers 
was finding a balance between achieving water solubility and avoiding rapid 
hydrolysis of the Si–O bonds.  In fact, only at the point when dendrimers of second 
generation were created having CH2CH2NMe2 branches outside of the Si–O were the 
dendrimers able to be dissolved in water without the immediate hydrolysis of the Si–
O bonds [109].  Thus, the quaternized version, possessing CH2CH2N+Me3 branches, 
offered all three characteristics of water solubility, a positively charged periphery and 
gradually hydrolysable internal Si–O bonds. Time-controlled hydrolysis was 
demonstrated clearly via NMR spectroscopy, and established the timeframe for a 
dendrimer possessing only a single ethylamine on each branch (2G-N8) to degrade 
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between 1 and 12 hours with a large percentage of it occurring after 5 h (Figure 25). 
More in-depth NMR analysis on concentration of intact dendrimer versus time 
showed a first-order decomposition that also was dependent on initial dendrimer 
concentration [109]. Due to the dependency on dendrimer concentration for the rate of 
Si–O hydrolysis, the dendrimer concentrations utilized in vivo would decompose at a 
slower rate than the higher concentrations of laboratory experiments. This timeframe 
for degradation would provide adequate time for transit in the blood stream to the 
target cells, cell transfection and escape from the endosome all to occur prior to 
liberation of the cargo. Furthermore, gel electrophoresis showed the liberation of 
siRNA to begin between 8 and 12 h and continue until the last of the siRNA had been 
freed between 18 and 24 h (Figure 26). A gradual but constant liberation would 
enhance therapy by providing a constantly replenishing supply of active siRNA 
molecules.  
The best way to observe protection of the delivery vehicle over its cargo was 
by monitoring siRNA using GE.  The presence of liberated siRNA versus the absence 
of siRNA indicated degradation by RNases. The first protection assay gel (Figure 27) 
showed intact siRNA in the presence of RNase when complexed to 2G-NN16. The 
fact that the siRNA band was retained in the well made quantitative analysis difficult, 
but visual inspection offered sound evidence of a high degree of protection. The gel 
showing heparin-freed siRNA (Figure 28) allowed for quantitative analysis using gel 
band intensity quantification software.  Results showed at least 40% of the siRNA 
was protected and subsequently liberated by heparin. PEI-PEG polymers had also 
been tested for protection from RNase by Mao, et al. [89]. Their research showed that 
polymers engrafted with larger PEG chains were the best at protecting siRNA.  20k 
maintained protection over at least 80% of the siRNA even when exposed to high 
concentrations of RNase; 5k protected at least 50% and 2k protected over 30% up 
until the two highest RNase concentrations were added to the polyplex. Meanwhile 
PEI(25k) and PEG(550) offered very little or no protection from RNase degradation. 
The capability of protecting siRNA from RNase is of fundamental importance for the 
siRNA to be able to exert an effect once in the interior of the cell [89].  Previously, 
we found that CBS similarly protected oligonucleotides from sequestration and 
degradation by serum proteins [122] and [123]. Protection from RNase degradation 
and sequestration by other proteins is a major benefit of these delivery vehicles as 
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naked siRNA cannot be administered intravenously without being rapidly lost to the 
body’s natural defenses contained in the blood system. 
The next section of results revealed the cytotoxicity levels caused by the 
delivery vehicles and the complexes they formed with siRNA on the two types of 
cells under investigation.  First off, dendriplexes at concentrations up to 25 µg/ml did 
not cause sufficient membrane rupture to cause cytotoxicity in any of the cells tested. 
They did not damage cell metabolism as measured by MTT assays. They did not 
cause loss of cell viability according to flow cytometry scatter plots. The results from 
these experiments came about while assaying for siRNA uptake by cells treated with 
varying concentrations of dendriplex. It was seen that the percentages of total events 
that fell within the “viable” gates varied according to the treatment. This resulted in a 
simple assay for testing viability without staining. Some forms of staining could have 
further distinguished apoptotic or necrotic cells from live cells [124], but possibly 
would have interfered with quantification of uptake.  Next, it was found that 
dendriplex at these concentrations did not cause cell proliferation as measured by 
absolute cell counts or DNA synthesis. However, the BrdU incorporation into newly 
synthesized DNA assay is less accurate than others at estimating cell viability because 
it only indicates the extent of DNA replication, not cell proliferation. Dendrimers did 
not result in over- or under-expression of any gene in astrocytes compared to control 
cells as seen in the genome-wide microarray.  Most importantly, no apoptosis 
inducing or cell cycle arrest promoting genes were affected by 24 µg/ml 2G-NN16 
treatments. True, dendrimers alone were more toxic than dendriplexes.  However, 
neither dendrimers alone nor dendriplexes were as toxic as Lipofectin at working 
concentrations. Additionally, dendriplexes did not have a toxic effect on HIV-infected 
PBMC, even though productive HIV infection can substantially weaken the cells’ 
fitness making them more susceptible to cytotoxic damage. 
It is relevant that 2G-NN16 did not produce cytotoxicity in the human 
astrocytoma cells. The results of MTT and LDH screening showed that the upper 
limit of the 2G-NN16 concentration for biological assays is no less than 24 µg/ml. 
Toxicity profiles of dendriplexes formed from 2G-NN16 CBS and siRNA showed 
very similar values to those obtained for dendrimers alone, as has been reported 
elsewhere [107, 113, 125, 126]. Both assays indicate a lack of toxicity of 2G-NN16 at 
the concentrations used in HIV inhibition experiments. Until now, gene expression 
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studies about toxicity of delivery reagents are not routinely performed. Here, we have 
performed a microarray analysis of the U87MG astrocytoma cell line treated with 24 
µg/ml of 2G-NN16 compared to control cells. These studies did not show any 
statistically significant gene expression change [127, 128], so we can consider 2G-
NN16 to be a transfection agent with minimal secondary effects in gene regulation in 
astrocytoma cells. To test for possible off-target effects by the siRNA, further 
microarray analyses must be performed on cells treated with dendriplexes containing 
siRNA or siRNA alone. These results contrast with changes in gene expression 
profiles [129, 130] and higher cytotoxic effects [104, 131, 132] described for other 
dendrimers. 
For cytotoxicity testing of PEI-PEG polymers, initially, they were tested on 
mouse cells.  The order of toxicity from most to least was PEI25k, PEG(5k)2, 
PEG(30k)1 and PEG(550)30. Testing on SupT1 and PBMCs revealed practically the 
same results showing the order of toxicity to be PEI25k, PEG(20k)1, PEG(5k)4, 
PEG(2k)10, and PEG(550)30. Differences between the toxic effects of PEG(5k)2 and 
PEG(5k)4 in these two assays revealed that only two PEG blocks of 5k in size were 
not sufficient to protect cells from the PEI core while four 5k blocks appeared to be. 
The use of flow cytometry to estimate cell viability was also utilized with PEI-PEG 
treated cells. Both SupT1 and PBMC treated with polyplexes (Figures 47 and 48) 
produced results in accordance with LDH assays (Figures 43 and 45).  The 
similarities in the viability graphs produced by these two methods give support to the 
validity of flow cytometry to detect cytotoxicity. Finally, PEI(25k) at high 
concentrations was seen to cause both erythrocyte rupture and aggregation, but 
neither PEG(20k)1 nor PEG(550)30 appeared to cause negative effects on these cells, 
except for a possible slight tendency to aggregate for treatment with PEG(20k)1.  
These results must be interpreted with the fact that the polymer concentrations were 
15 times the usual amount administered (0.25 mg/ml for the PEI-PEG copolymers). 
When assessing the transfection efficiency of the various delivery agents, both 
flow cytometry and confocal/immunofluorescence microscopy were used. Accurate 
quantification of uptake was measured by flow cytometry, while qualitative 
assessment of the nature of the uptake was done via confocal and 
immunofluorescence microscope images. Positive results showed that dendriplex was 
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successful at transfecting SupT1, HIV-infected PBMC and U87MG cells. Also, 
siRNA alone was taken up by all the cells. For incubation times of 24 h, dendrimer-
delivered siRNA improved the transfection efficiency over siRNA alone.  The gradual 
degradation of the dendrimer could feasibly explain this difference, as siRNA is more 
easily detected after being liberated from the dendrimer. For astrocytes, the higher the 
+/- ratio, the better the transfection, while for lymphocytes, the highest transfection 
efficiency was at a +/- ratio of 2.  This is possibly explained by astrocytes’ reduced 
tendency to endocytose foreign particles [133], and the increased zeta potential of the 
dendriplexes at higher +/- charge ratios greatly facilitates this process.  Meanwhile, 
the higher zeta potential dendriplexes causes more harm than good to lymphocytes. It 
is worth noting, however, that dendriplexes showed equal or better transfection than 
the commercially available Lipofectin.  This is a noteworthy result considering that 
Lipofectin is among the top of the line transfection reagents used for laboratory 
settings.  
 The fact that we observed complete entrance of naked siRNA in the primary 
lymphocytes and the U87MG within 24 hours and almost immediately in the 
established cell line merits attention.  This is not the first time that we have noticed 
this occurrence as we also observed the uptake of free oligonucleotides in PBMC 
[134].  It can be assumed that the small size of the siRNA and antisense 
oligonucleotides is the determining factor in their uptake since we have not witnessed 
the entrance of larger plasmids alone (data not shown).  Regardless of their uptake by 
these cells, naked siRNA and oligonucleotides would face more significant obstacles 
in the in vivo setting, precisely for which the dendrimers and polymers were designed 
to overcome.  The design of these delivery vehicles not only intends to improve 
transfection efficiency, stability and protection in vivo, but also to possess a time-
dependent release capability in the case of dendrimers, and an exterior layer of PEG 
moieties to improve biocompatibility in the case of polymers. 
For polyplex treatments administered with a constant siRNA concentration, 
successful transfection was achieved in lymphocytes by almost all polymers even 
after short incubation times. PEG(20k)1, interestingly, was better at transfecting 
PBMC than SupT1, while PEG(550)30 showed the exact opposite characteristic. 
PEI(25k) achieved quicker transfection in both cell types, but by 24 h, its high 
transfection efficiency was equaled by the other copolymers.  It is also uncertain if the 
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high uptake at short time periods was because of cellular damage caused by the 
PEI25k polymer, which is a possibility considering the toxicity results for this 
polymer after 3 h. showed consistent transfection capability for all times, N/P ratios 
and cell types.  This result, in particular, was of more significance when considering 
the results obtained for biological effect achieved with PEG(2k)10-delivered siRNA.  
Confocal and immunofluorescence images proved that flow cytometry results 
indicated uptake into the interior of the cell and not just association of the siRNA with 
the cell membrane.  Additionally, the videos of live cells positive for siRNA uptake 
proved that the transfection was not the result of fixating the cells (which was not 
performed, in this case) or any other process of the cell preparation that would have 
created pores in the cell membrane, but rather by natural uptake. For confocal images 
of polyplex treated cells, double the siRNA concentration was administered to 
increase the probability of obtaining a clearer detection of the siRNA.  The drawback 
was that this resulted in double the concentration of polymer, which resulted in a 
cytotoxic effect for PEG(20k)1 and especially PEI(25k). 
  A substantial problem in investigating gene therapy or RNAi in the fight against 
HIV lies in the fact that practically all HIV-susceptible cells are very difficult to 
transfect [135, 136].  To overcome the inherent difficulties in transfecting suspension 
T cell lines or primary cell cultures such as PBMC or NHA [137], investigators have 
made use of innovative techniques such as nucleofection [138] or antibody fused 
proteins [139].  The confocal microscopy images indicate uptake of siRNA by CD4+ 
T lymphocytes via our transfection methods. Moreover, the similarity of the 
compartmentalized fluorescent siRNA with perinuclear endosomes in terms of 
morphology and spatial localization indicate the possibility of entrance via 
endocytosis.  In several polarized T cells seen in the videos, fluorescence appears 
clearly accumulated in the uropod.  This peculiar localization only occurs in polarized 
lymphocytes [140], offering further evidence of endocytosis.  Even though the exact 
internalization pathway has not yet been determined, it is most likely that the pathway 
is mediated by internal vesicle formation. 
In order to better assess the potential for dendrimers to treat cells of the CNS, 
quality assays on biological barrier transcytosis of the molecules were needed. The 
first assays involved a monolayer of polarized epithelial cells, which is used in the 
laboratory to model the genital mucosal membrane [141]. After obtaining positive 
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results for the ability to cross the epithelial cell layer, bovine brain microvascular 
endothelial cells were obtained.  These cells form a monolayer that more closely 
mimics the cells contained in the BBB [142, 143]. In order for the models to function, 
it was essential that the cells formed tight junctions without fenestrations [117]. We 
analyzed the monolayers during their growth using several methods capable of 
detecting gaps and fenestrations. First, visual analysis of the monolayer was 
accomplished with the aid of a light microscope, a Nomarski prism for depth 
perception and AgNO3 staining, which highlights tight junctions [144]. Monolayer-
forming cells were seeded and grown concurrently both in the transwell dishes and in 
separate plaques which could be viewed under a microscope.  This allowed for the 
determination of the progress of the development of the monolayer. Second, an 
epithelial voltohmmeter was used to measure the TEER, and only a reading of greater 
than 300 Ωcm2 was considered sufficient to indicate the absence of junction gaps. 
However, the strongest evidence for the integrity of the tight monolayer was the fact 
that after 5 h, there was no uptake of either siRNA alone or dendriplex in either 
PBMC or U87MG for either of the barrier models.  Had there existed gaps, there most 
certainly would have been transfection in these cells after 5 h, because transfection 
studies had already shown that 3 h is enough for the transfection of these cells with 
dendriplex or siRNA in most cases. Therefore, the high transfection rate after 72 h 
can only be considered a result of the dendriplexes crossing the barrier.  
The CNS is not the primary target for HIV infection.  However, the existence 
of neuropathological disorders caused by HIV infection such as HIV associated 
dementia (HAD) combined with the inaccessibility of the CNS for large molecule 
pharmaceuticals creates the need for research into anti-HIV therapy for the CNS 
including drugs with the capability of crossing the blood brain barrier. Although the 
introduction of HAART has greatly reduced the severity of HAD, still a great number 
of HIV-infected individuals manifest a plethora of CNS diseases unrelated to 
opportunistic infections, including HAD [22-24]. The majority of antiretroviral drugs 
may not cross the BBB sufficiently to reduce the viral load and inflammation in the 
CNS. Thus, HAART is currently insufficient in many cases. However, the emergence 
of nanotechnology provides some hope that treatment of CNS disorders in HIV-
infected patients will be improved.  
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The final section of results presented in this work dealt with achieving a 
desired outcome from treatment with the complexes, namely, specific gene silencing. 
For many of the gene silencing experiments, the housekeeping gene GAPDH was 
targeted as an easily measured control for the detection of effective gene silencing.  
When siRNA targeted to either GAPDH or the HIV genes was transfected into 
lymphocytes via electroporation, the result was a sequence-specific, lasting 
downregulation of the target genes.  These results supported the effectivity of the 
siRNA if transfection and release could be accomplished with the delivery agents.  
They also revealed that the silencing activity was dependent on the siRNA 
concentration and established the most effective concentration to be at least 250 nM.  
Experiments in delivery of siRNA to lymphocytes by 2G-NN16 showed nearly 50% 
silencing of GAPDH and 22% inhibition of HIV.  In astrocytes the maximum 
silencing efficiency was 37% and over 80%, respectively.  Furthermore, in astrocytes, 
the treatment was able to have an effect at reducing the viral replication for both an 
X4-HIV isolate (NL4-3) and an R5-HIV isolate (Ba-L).  Being able to silence both 
viral isolates is promising, as the exact mechanism of how HIV infects CNS cells is 
not fully understood. 
As for polymer-delivered siRNA to lymphocytes, the short-term silencing 
effect was less promising.  However, when repetitive treatments were administered 
throughout the duration of longer experiments, both GAPDH and HIV were silenced 
with much higher effectivity.  Two copolymers stood out over the remaining three 
polymers in their ability to affect gene expression. These were PEG(2k)10 and 
PEG(20k)1. Delivery by PEG(2k)10 had somewhat less of a sequence-specific effect in 
the longer duration experiments.  However, it seemed to have a bit more effectivity 
after shorter incubation times, and was indeed able to inhibit HIV replication during 
the long-term experiments by delivering siNEF by an average of 74% compared to 
siRandom starting from day 5 in cells that had been infected with HIV at a MOI of 
100 pg/106 cells (Figure 73). The logarithmic scale of the antigen p24 production in 
this graph causes the results to be misleading in the extent of the differences between 
the treatments.  That, and the fact that PEG(20k)1-delivered siNEF achieved an almost 
total degree of inhibition compared either to untreated cells or siRandom treated cells. 
The most astonishing results of this work were the capability of PEG(20k)1-delivered 
siNEF at inhibiting HIV when administered regularly every few days for multiple 
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weeks. In cells infected with a MOI of 100 pg/106 cells, PEG(20k)1-delivered siNEF 
resulted in an average inhibition of 90 % compared to siRandom and 99.8% compared 
to untreated cells after day 7. Naturally, it is difficult to extrapolate what kind of 
inhibitory effect this treatment would have in patients, as the level of virus production 
in laboratory experiments is purposely maintained at very high levels in order to 
detect sometimes-subtle differences in replication rates.  Of course, in vivo tests 
would provide much needed information about the effect of these treatments when 
applied to whole organisms.   
 Currently there exist many limits in the overall efficacy of current HIV 
therapy because of the ability of HIV to develop drug resistant strains.  Likewise, 
viral latency is a significant problem when addressing treatment for HIV infection 
[145] and [146].  RNAi could potentially improve this weakness in HIV therapy by 
attacking very specific targets of the viral life cycle [147], reducing the opportunities 
for the emergence of resistant strains, and making use of a cocktail of siRNA to attack 
the virus on multiple fronts. As we have shown, a mixture of several siRNA targeted 
specifically to the virus resulted in an inhibitory effect of nearly 40%.  This inhibition 
was achieved by only targeting a mixture of HIV genes, however the possibility of 
combining [64] siRNA targeted to HIV with other siRNA designed to downregulate 
endogenous cellular genes [37, 148] essential for HIV replication could feasibly 
improve results.  Furthermore, dendriplexes or polyplexes could be utilized to 
selectively target HIV infected cells or harbors of latently infected cell pools. 
This work has combined three separate but equally interesting aspects of 
molecular biology research.  First, nanotechnology is a field continually expanding 
and offering new nanoparticles and nanosystems for a huge variety of applications. 
Research into the utilization of nanoparticles such as dendrimers and polymers as 
biocompatible drug delivery cell-transfecting vehicles requires inorganic structural 
chemistry combined with cellular biology. Second, RNAi is an exciting laboratory 
tool currently at the perusal of molecular biologists for a myriad of research 
applications. It is also being developed and tested for potential uses outside the 
laboratory and in the realm of the hospital for clinical uses including, as one example, 
the fight against infectious diseases [147]. Finally, HIV is a raging pandemic of huge 
proportions that requires the development and availability of as many weapons and 
defenses against it as possible. By examining the possibility of bringing 
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nanotechnology and RNAi together as a therapy against HIV infection, this work, 
hopefully, will in some way contribute to the ongoing research towards a solution to 
this disease and in the process add to the ever expanding base of knowledge being 
constantly generated in the scientific laboratory. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSIONS 
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1. 2G-NN16 dendrimer forms a stable dendriplex with siRNA at an optimal +/- 
ratio between 2 and 4, which possesses a particle size from 250 to 350 nm, 
protects the siRNA from RNases, and exhibits a time-controlled liberation of 
its siRNA cargo from 12 to 24 h. 
 
2. The non-grafted PEI polymer forms a stable polyplex at an N/P ratio of 5, 
while the PEG-grafted PEI polymers form polyplexes starting from an N/P 
ratio of 8. The larger PEG moieties allow for the formation of particles around 
150 nm in size, which possesses a zeta potential of +15 mV. 
 
3. When treated at working concentrations, 2G-NN16 dendrimer and dendriplex 
do not cause cytotoxicity or cell proliferation on immortalized or primary 
lymphocytes or astrocytes. Neither do they cause erythrocyte hemolysis. 
Furthermore, 2G-NN16 alone does not cause gene expression variations in 
astrocytes. 
 
4. PEG engraftments improve the biocompatibility profile of PEI polymers on 
lymphocytes, especially PEG chains of the sizes 0.55, 2 and 5 kDa. 
Regardless, none of the polymers were cytotoxic when administered at twice 
the necessary working concentrations. 
 
5. By 24 h, 2G-NN16 dendriplex can achieve very high transfection efficiencies 
in lymphocytes and astrocytes. The optimal +/- charge ratio for transfection is 
2 for lymphocytes and 8 for astrocytes. 
 
6. Ungrafted PEI polymer achieves cell transfection more quickly than grafter 
copolymer, but by 24 h, all the polymers show relatively equal transfection 
efficiencies. 
 
7. Transfection facilitated by polyplex or dendriplex resulted in access to the cell 
interior by siRNA. 
 
8. 2G-NN16 dendriplex was capable of crossing biological barrier models made 
of polarized epithelial or bovine brain microvascular endothelial cells and 
achieving transfection of lymphocytes or astrocytes on the opposite side of the 
barrier. 
 
9. siRNA delivered by 2G-NN16 successfully reduced GAPDH expression or 
HIV replication in lymphocytes or astrocytes in a sequence-specific manner. 
 
10. Treatment of lymphocytes with polyplexes composed of siRNA and PEI(25k)-
PEG(20k)1 resulted in nearly 80% gene silencing of GAPDH when 
administered regularly every few days for multiple weeks. The ability to 
inhibit viral replication in HIV-infected lymphocytes with siRNA targeted to 
viral genes by this same treatment regimen was achieved to the extent of at 
least a 10-fold reduction in virus production. 
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